



Contents

2	Corporate Information
3	Financial Highlights
4	Management Discussion and Analysis
30	Report on Review of Condensed Consolidated Financial Statements
31	Condensed Consolidated Income Statement
32	Condensed Consolidated Statement of Comprehensive Income
33	Condensed Consolidated Statement of Financial Position
35	Condensed Consolidated Statement of Changes In Equity
36	Condensed Consolidated Statement of Cash Flows
38	Notes to the Condensed Consolidated Financial Statements
64	Other Information

Corporate Information

BOARD OF DIRECTORS

Executive Directors:

CAI Dong Chen (*Chairman*)

CAI Lei (*Vice-Chairman and Chief Executive Officer*)

WEI Qingjie (*Vice-Chairman and Chief Operating Officer*)

ZHANG Cuilong

WANG Zhenguo

LI Chunlei

YAO Bing

CAI Xin

CHEN Weiping

QU Zhiyong

ZHANG Yiwei

Independent Non-executive Directors:

WANG Bo

CHEN Chuan

WANG Hongguang

AU Chun Kwok Alan

LAW Cheuk Kin Stephen

LI Quan

AUDIT COMMITTEE

AU Chun Kwok Alan (*Chairman*)

WANG Bo

CHEN Chuan

NOMINATION COMMITTEE

CAI Dong Chen (*Chairman*)

WANG Bo

CHEN Chuan

LI Quan

REMUNERATION COMMITTEE

AU Chun Kwok Alan (*Chairman*)

WANG Bo

CHEN Chuan

COMPANY SECRETARY

LO Tai On

REGISTERED OFFICE

Suite 3206

32nd Floor

Central Plaza

18 Harbour Road

Wan Chai

Hong Kong

SHARE REGISTRAR

Tricor Investor Services Limited

17/F, Far East Finance Centre

16 Harcourt Road

Hong Kong

AUDITOR

Deloitte Touche Tohmatsu

Registered Public Interest Entity Auditors

PLACE OF LISTING

The Stock Exchange of Hong Kong Limited ("HKEx")

STOCK CODE

1093

WEBSITE ADDRESS

www.cspc.com.hk

Financial Highlights

	Six months ended 30 June		
	2026	2025	Change
<i>(in RMB'000, unless otherwise stated)</i>			
Revenue by business units:			
Finished drugs	16,060,711	10,247,652	+56.7%
Bulk products	1,660,385	2,074,708	-20.0%
Functional food and others	873,398	951,056	-8.2%
Total revenue	18,594,494	13,273,416	+40.1%
Profit attributable to shareholders of the Company			
Reported	6,094,212	2,547,851	+139.2%
Underlying <i>(note)</i>	6,164,279	2,319,521	+165.8%
Earnings per share <i>(RMB cents)</i>			
Based on reported profit attributable to shareholders of the Company			
— Basic	53.45	22.29	+139.8%
— Diluted	53.36	22.29	+139.4%
Interim dividend per share <i>(HK cents)</i>	18.00	14.00	+28.6%

Note: Underlying profit attributable to shareholders of the Company, a non-HKFRS Accounting Standards measure, represents the profit attributable to shareholders of the Company before taking into account fair value changes on financial assets measured at fair value through profit or loss ("FVTPL") and employee share-based compensation expenses. A reconciliation between reported and underlying profit is provided on page 28 of this report.

Management Discussion and Analysis

RESULTS IN THE FIRST HALF OF 2026

In the first half of 2026, the Group recorded revenue of RMB18,594 million and reported profit attributable to shareholders of the Company of RMB6,094 million, representing increases of 40.1% and 139.2%, respectively, as compared with the same period last year. Excluding fair value changes on financial assets measured at FVTPL and employee share-based compensation expenses, underlying profit attributable to shareholders of the Company amounted to RMB6,164 million, representing an increase of 165.8% as compared with the same period last year.

Basic earnings per share based on reported profit attributable to shareholders of the Company as shown in the financial statements amounted to RMB53.45 cents, representing an increase of 139.8% as compared with the same period last year.

DIVIDEND AND SHARE BUY-BACKS

The Board has declared an interim dividend of HK18 cents per share for 2026 (interim dividend for 2025: HK14 cents per share). The dividend will be payable on Tuesday, 10 November 2026 to shareholders whose names appear on the register of members of the Company on Monday, 26 October 2026.

In the first half of 2026, the Company utilised HK\$321 million through the trustee for share purchases under the share award scheme, purchasing a total of 46,178,000 shares to continue incentivising its employees to make greater contributions to the Group's development.

COMPANY OVERVIEW

CSPC is a comprehensive pharmaceutical enterprise integrating Research and Development ("R&D"), manufacture and sales with innovation as its core driver. With the corporate mission of "All for good medicine, all for mankind's health", we are committed to focusing on unmet clinical needs, continuously overcoming bottlenecks in clinical treatment through technology innovation, and truly benefiting the vast number of patients.

IMPLEMENTING THE DUAL-ENGINE STRATEGY TO STRENGTHEN CORE COMPETITIVENESS

"Leading Innovation and Creating an Excellent CSPC" is our core vision. Under the leadership of the Chairman and guided by the dual-engine strategy of "Innovation and Internationalisation", the Group has consistently adhered to increasing its investment in R&D and strengthening team building, resulting in a significant enhancement of its core competitiveness, which provides strong momentum for the Group's long-term sustainable development.

ENHANCING R&D PLATFORMS AND GAINING INDUSTRY RECOGNITION

The Group has an internationalised R&D team with more than 2,000 professionals and R&D centers located in major cities in China and the U.S., with focus on key therapeutic areas such as oncology, cardiovascular, nervous system, respiratory, anti-infectives, and digestive and metabolic diseases. We have taken the lead in establishing an industry-leading AI drug discovery technology platform and a globally leading delivery technology system, building significant differentiated advantages in the industry. Its pipeline covers frontier areas such as ADC, antibody drugs, CAR-T products, long-acting peptide formulations, and nucleic acid drugs. In general, the Group has built eight innovative technology R&D platforms, including nano-formulations, mRNA, siRNA, antibody/fusion proteins, cell therapy and antibody-drug conjugates, which provide solid technical support for the discovery and translation of innovative drugs.

Management Discussion and Analysis

In terms of international recognition, the Group has been included in the Global Top 25 Pharma Companies by Pipeline Size published by the internationally renowned consulting firm Citeline for four consecutive years. In the 2026 ranking, the Group was ranked 15th globally, climbing four places from the previous year. In terms of scientific and technological innovation achievement, the Group has won the Second Prize of the National Award for Science and Technology Progress four times, the China Grand Awards for Industry twice and the China Patent Gold Prize three times. The Group has also been recognised as a “National Innovative Enterprise” and a “National Enterprise Technology Center”. The Group owns two national key laboratories, including the “National Key Laboratory for New Pharmaceutical Preparations and Excipients” and the “National Engineering Laboratory for Chiral Drugs”. In addition, the Group has jointly established the “National Nano Intelligent Manufacturing Industry Innovation Center”, the only national-level innovation platform in the nano-industry in collaboration with The GBA National Institute For Nanotechnology Innovation.

ADVANCING CLINICAL TRIALS AND PUBLISHING MAJOR ACADEMIC ACHIEVEMENTS

In the first half of 2026, the Group obtained a total of 30 IND approvals, secured marketing approvals for seven key products, and initiated 18 pivotal phase III clinical studies. Since the beginning of the year, multiple research achievements have been published in leading international medical journals. The phase I clinical study results of SYS6010 in non-small cell lung cancer were accepted for publication by *Cancer Cell* (impact factor: 56.1). The phase III study results of docetaxel (albumin-bound) in combination with KN026 as neoadjuvant therapy for breast cancer were accepted for publication by *JAMA Oncology* (impact factor: 23.9). The phase III clinical study results of albumin-bound paclitaxel (SYHX2011) for the treatment of patients with advanced breast cancer were accepted by *Cancer Communications* (impact factor: 24.9). These results demonstrate the recognition of the Group’s research capabilities by leading international scientific journals. Meanwhile, the Group presented its key research findings on multiple occasions at leading international academic platforms, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the Society of Gynecologic Oncology (SGO). In the first half of 2026 alone, the Group has presented 14 research findings, including five oral presentations, which received positive international feedback and attracted broad attention from the communities. At present, the Group has more than 200 innovative drugs and preparations under R&D, including over 90 large molecule drugs, over 60 small molecule drugs, and over 50 new preparations. Some of them have promising market prospects and demonstrate significant superiority over existing therapies in efficacy and safety.

BUILDING AI-DRIVEN CORE COMPETITIVENESS IN PHARMACEUTICALS AND ACCELERATING INNOVATIVE R&D AND TRANSFORMATION

CSPC’s exploration in the field of AI drug discovery began in 2011 with the establishment of its CADD (Computer-Aided Drug Design) laboratory. At present, the Group has built AI drug discovery teams across Shijiazhuang, Beijing, and Shanghai, forming a technological framework centred around the “AI-Engine Dual-Drive Drug Discovery Platform”. The platform has achieved one-stop development capabilities, ranging from target discovery, molecule generation, and structure prediction to ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction.

AI technology has been deeply integrated into the entire new drug R&D process, encompassing stages such as target discovery, molecular design, and clinical trial optimisation. Its application scope has also expanded from initial small molecule drug screening to various cutting-edge fields, including antibody screening, nucleic acid screening, mRNA sequence optimisation, and protein modification.

AI empowerment has significantly boosted R&D efficiency. CSPC’s early-stage new drug discovery time has been reduced by over 30%, R&D costs have been halved, and the accuracy of candidate compound screening has increased by nearly threefold. Furthermore, the overall R&D success rate in early-stage screening has improved by 50% to 60%.

Management Discussion and Analysis

The strength of the Group's AI drug discovery platform has been validated through a series of massive out-licensing (BD) deals. Since 2024, the Group has reached four major agreements with the global pharmaceutical giant AstraZeneca, with the cumulative potential total value of these collaborations reaching approximately US\$27.6 billion.

The Group's achievements in the field of AI drug discovery have received authoritative recognition, establishing its industry-leading position. Its in-house developed "AI-Engine Dual-Drive Drug Discovery Platform" was successfully selected as an exemplary case for the 2025 digital transformation "Digital Three Goods" (Shuzi Sanpin) initiative by the Ministry of Industry and Information Technology (MIIT) of China.

Through a dual-drive model of "internal R&D + external collaboration", the Group has successfully transformed AI technology into the core competitiveness of its innovative drug research and development. Its technological value has not only been validated by massive collaborations with international giants but has also gained national-level authoritative recognition, making it a prime example of a Chinese pharmaceutical company achieving innovative transformation through AI technology.

In addition, the Group proactively benchmarks against the standards of "intelligent manufacturing and internationalisation", comprehensively introducing Industry 4.0 technologies such as 5G, the Internet of Things (IoT), artificial intelligence, cloud computing, and robotics. Through this, our pharmaceutical production has achieved precise control throughout the entire process and full-lifecycle traceability of our products. These measures not only ensure the long-term stable operation of the production system but also significantly enhance overall production efficiency.

DEEPENING GLOBAL STRATEGY AND EXPANDING INTERNATIONAL R&D AND MANUFACTURING COLLABORATIONS

In terms of internationalisation, driven by innovative R&D as our engine, the Group is advancing its global strategic deployment to build a worldwide pharmaceutical value ecosystem. In terms of global R&D positioning, by implementing the strategy of "dual China-US regulatory submission", we initiate a number of multi-center clinical trials across Europe and America. The Group has established R&D systems and quality platforms that meet international standards, laying a solid foundation for global product launches. Regarding overseas expansion of innovative products, since the beginning of 2026, the Group entered into two strategic R&D collaborations with AstraZeneca, an internationally renowned pharmaceutical company, on long-acting delivery technology platform, AI-enabled peptide drug platform, and small nucleic acid platform, with total contract value of US\$20.27 billion, further deepening the global strategic layout across its products of various platforms. In August 2026, the Group entered into a joint venture contract with AstraZeneca to build a next-generation biologics manufacturing base in Shijiazhuang, China, to further deepen the strategic cooperation. The establishment of this joint venture also marks the extension of the Group's internationalisation path from "product and technology going global" to "production system and supply chain capability going global".

CONSOLIDATING COMMERCIAL NETWORKS TO DRIVE INNOVATION TRANSFORMATION

The Group possesses a well-established and robust commercialisation capability, supported by a professional marketing team of over 10,000 employees covering medical institutions and retail channels nationwide. We are actively advancing market penetration into lower-tier regions and deepening our presence in county-level grassroots markets to deliver high-quality drugs to the public. Our experienced sales system and rich commercialisation experience provide a solid foundation for the launch and market performance of the Group's innovative drugs in the future.

Looking ahead, the Group will continue to drive development through technological innovation, and leverage its robust commercialisation capabilities to support the high-quality development of China's pharmaceutical industry and bring benefits to more patients.

BUSINESS REVIEW

FINISHED DRUG BUSINESS

In the first half of 2026, the major changes in pharmaceutical policies and industry conditions are as follows:

- In March 2026, China's "15th Five-Year Plan" designated the biopharmaceutical sector as a national "emerging pillar industry" for the first time, and positioned biomanufacturing as a future industry, further elevating its strategic importance within the national industrial system. The Plan also proposes to improve the coordinated development and governance mechanism of medical services, medical insurance and pharmaceuticals, driving the upgrade of the "Three-Medical Linkage" from departmental-level reforms to systematical coordinated governance.
- From February to March 2026, the 11th batch of national centralised procurement was officially implemented, and the unified successive procurement for drugs covered in the 1st to 8th batches of national centralised procurement was formally put into effect. These reflect the continuous adjustment and improvement of the centralised volume-based procurement rules. The guiding principles of "ensuring stable clinical supply and curbing irrational internal competition", together with the mechanism under which medical institutions report procurement volumes by manufacturer, facilitated the centralised procurement to evolve from purely low-price competition to quality and brand competition, thereby guiding the adjustment of the pharmaceutical industry structure and the consolidation of the sector.
- In April 2026, the General Office of the State Council issued the Several Opinions on Improving the Drug Pricing Mechanism (《關於健全藥品價格形成機制的若干意見》), which states that a full-cycle, full-channel and full-scope drug pricing mechanism shall be established and improved, providing institutional support for the realisation of drug value and orderly market competition.
- In July 2026, the National Health Commission released the National Essential Medicines List (2026 Edition), which will directly affect clinical medication guidelines, formularies and drug stocking by medical institutions, and will take effect on 1 September 2026. Upon its implementation, medical institutions will be required to complete the adjustment of their stocking adjustments within a specified timeframe. The use of drugs not included in the list may face a narrower scope of clinical application.

ADDRESSING MARKET CHALLENGES TO DRIVE DIVERSIFIED REVENUE GROWTH

In response to the aforementioned policy changes, on one hand, the Group actively seized policy opportunities and responded to market challenges by advancing diversified strategies including academic development, market penetration into lower-tier regions, and expansion of retail channels, to enhance product market penetration and brand influence. Revenue from finished drugs recorded a significant year-on-year increase in the first half of 2026. On the other hand, the Group placed equal emphasis on strengthening its internal capabilities and intensifying R&D efforts, continuously increasing R&D investment and facilitating the launch of new products. By strengthening innovation capabilities and developing products with distinctive market advantages, the Group enhanced the competitiveness of its overall product pipeline. Meanwhile, the Group actively expanded its international footprint through out-licensing and international cooperation to tap into overseas markets. The abovesaid strategy has yielded notable results, with licence fee income becoming the Group's second growth driver. In the first half of 2026, the Group's licence fee income was RMB5,895 million, representing a year-on-year increase of 448.5%.

Management Discussion and Analysis

The finished drug business recorded a revenue of RMB16,061 million (including licence fee income of RMB5,895 million) for the first half of 2026, representing an increase of 56.7% as compared to the same period of previous year. The analysis of revenue from finished drug business is as follows:

	Six months ended 30 June		Change
	2026 (RMB'000)	2025 (RMB'000)	
By Therapeutic Area			
Nervous system	4,789,726	3,754,814	+27.6%
Oncology	1,005,654	1,050,606	-4.3%
Anti-infectives	1,681,396	1,656,912	+1.5%
Cardiovascular	1,033,051	868,336	+19.0%
Respiratory system	520,935	575,441	-9.5%
Digestion and metabolism	535,622	528,099	+1.4%
Others	599,358	738,777	-18.9%
Sales of goods	10,165,742	9,172,985	+10.8%
Licence fee income	5,894,969	1,074,667	+448.5%
Total revenue	16,060,711	10,247,652	+56.7%

Nervous System

Major products include NBP (恩必普®) (butylphthalide soft capsules/injection), Mingfule (明復樂®) (recombinant human TNK tissue-type plasminogen activator for injection), Shuanling (舒安靈®) (pentoxifylline extended-release tablets/injection), Enliwei (恩理維®) (lacosamide injection/tablets), Enxi (恩悉®) (pramipexole dihydrochloride tablets), Oushuan (歐舒安®) (paliperidone extended-release tablets), Ouyuexin (歐悅欣®) (desvenlafaxine succinate extended-release tablets) and Oulaining (歐來寧®) (oxiracetam capsules/oxiracetam for injection).

- **NBP (恩必普®)**

NBP is China's first Class 1 innovative chemical drug with independent intellectual property rights in the field of cerebrovascular diseases. It has received a total of 36 recommendations from professional institutions and clinical guidelines, and is primarily used for the treatment of ischemic stroke and related diseases, making it one of the core therapeutic agents for the clinical diagnosis and treatment of this indication. NBP has currently launched four "14th Five-Year" research projects. Among these, the BLESS study on mild stroke and the IMPACT study on cerebral small vessel disease, both initiated in 2025, are designed to generate high-level clinical evidence for NBP's sequential treatment regimen and long-term medication strategies spanning six months to one year, thereby further solidifying its clinical position in stroke management. In July 2026, both the capsule and injection formulations of NBP were included in the National Essential Medicines List (2026 Edition), which will significantly facilitate the development and application of the product in the primary healthcare market.

Management Discussion and Analysis

- **Mingfule (明復樂®)**

Mingfule is a third-generation specific thrombolytic drug independently developed with complete independent intellectual property rights. As the first tenecteplase product approved in China for the indication of acute ischemic stroke (AIS), it has been included in multiple clinical treatment guidelines. In January 2026, the American Heart Association (AHA) and the American Stroke Association (ASA) jointly released the 2026 Guidelines for the Early Management of Patients with Acute Ischemic Stroke, formally elevating tenecteplase to a first-line intravenous thrombolytic agent on par with alteplase. As a representative Chinese-developed tenecteplase, Mingfule has received official recognition from internationally authoritative guideline. During the first half of 2026, four research findings pertaining to Mingfule (TRACE-5, OPTION, INSTANT and TAPIS) were successively published in four of the world's leading medical journals, further strengthening the high-level evidence base supporting the Company's products and laying a solid foundation for their broader standardised clinical application. At present, the forward-looking clinical development pipeline for Mingfule continues to advance, with a registrational clinical study for thrombolytic treatment of AIS within 4.5 to 24 hours of symptom onset already initiated. Upon approval of this indication, Mingfule is expected to become the first thrombolytic drug in China to cover a 24-hour thrombolysis treatment window, thereby further expanding the eligible patient population and unlocking the product's long-term value.

- **Shuanling (舒安靈®)**

Shuanling is a non-selective phosphodiesterase inhibitor that can synergistically improve microcirculation disorders leveraging multiple mechanisms of action. Its clinical indications are continually expanding into the fields of endocrinology and nephrology. The market potential is expected to further expand as the doctors having an enhanced understanding of the product and the continuous penetration into lower-tier markets.

In the first half of 2026, NBP (恩必普®) continued to deepen its presence in the lower-tier and out-of-hospital markets, achieving a significant year-on-year increase in sales revenue. With the continuous strengthening of evidence-based medical data and enhanced clinical recognition of specific thrombolytic drug, Mingfule (明復樂®) recorded a substantial year-on-year sales revenue growth. Ouyuxin (歐悅欣®) and Shuanling (舒安靈®) also recorded a significant year-on-year increase in sales revenue, while Enxi (恩悉®) and Oushuan (歐舒安®) experienced slight year-on-year declines in sales revenue.

Oncology

Major products include Duoenyi (多恩益®) (irinotecan hydrochloride liposome injection), Jinyouli (津優力®) (PEG-rhG-CSF injection), Ennituo (恩尼妥®) (Anbenitamab injection), Xinbaizi (欣柏梓®) (paclitaxel for injection (albumin-bound) II), Keaili (克艾力®) (paclitaxel for injection (albumin-bound)), Duoenda (多恩達®) (mitoxantrone hydrochloride liposome injection), Enshuxing (恩舒幸®) (enlonstobart injection), Geruite (戈瑞特®) (lenvatinib mesilate capsules) and Jinlitai (津立泰®) (narlumosbart injection).

- **Duoenyi (多恩益®)**

Duoenyi is the first generic irinotecan hydrochloride liposome injection in China. It was approved in September 2023 for use in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic pancreatic cancer that have progressed after receiving gemcitabine treatment. In December 2025, Duoenyi secured approval for an additional indication, enabling its combination therapy with oxaliplatin, 5-FU and LV for the first-line treatment of metastatic pancreatic cancer, becoming the first irinotecan hydrochloride liposome injection approved for the first-line treatment of pancreatic cancer in China. Both the CSCO Guidelines and CACA Guidelines list the combination regimen as a recommendation for the treatment of metastatic pancreatic cancer in first-line, second-line and beyond.

Management Discussion and Analysis

- **Jinyouli (津優力®)**

Jinyouli is the first long-acting white blood cell booster drug independently developed in China. It is a Class 1 new therapeutic biological drug used to prevent and treat incidence of infection and pyrexia due to low neutrophil count in patients receiving chemotherapy. Through PEG modification technology, the product significantly improves administration convenience and patient compliance, and has been consistently recommended by authoritative guidelines domestically and internationally, winning multiple national-level awards.

- **Duoenda (多恩達®)**

Duoenda, a Class 2 new chemical drug independently developed by the Group, which was included in the National Reimbursement Drug List (“NRDL”) in 2023 for the treatment of relapsed/refractory peripheral T-cell lymphoma, is the world’s first mitoxantrone liposomal formulation to obtain market approval and has secured patent authorisations across multiple countries. At present, Duoenda is advancing clinical exploration for multiple hematologic malignancy indications, including front-line treatment of peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma, and acute myeloid leukemia. Concurrently, the Company is accelerating its overseas market expansion to promote the international application of this product.

- **Enshuxing (恩舒幸®)**

Enshuxing is a Class 1 new therapeutic biological drug, for which the Group owns the invention patent and complete independent property rights. The product was included in the NRDL in 2024. Enshuxing, a recombinant anti-PD-1 fully human monoclonal antibody, is indicated for the treatment of recurrent or metastatic cervical cancer with PD-L1 expression positive (CPS $\geq$ 1) in patients who have failed at least first-line of platinum-containing chemotherapy. Clinical data have demonstrated that Enshuxing, in combination with first-line therapy for patients with recurrent or metastatic cervical cancer, achieved a median progression-free survival (mPFS) of 15.1 months, showing significantly superior efficacy compared to similar products. In second-line and later-line monotherapy for patients with recurrent or metastatic cervical cancer, the median overall survival (mOS) reached 21.3 months. Leveraging outstanding clinical data, this product has been recommended in the guidelines of three major associations, namely the Chinese Medical Association, CSCO, and CACA. The market promotion of Enshuxing is primarily focused on gynecological tumors (including cervical cancer and endometrial cancer), while also actively advancing its clinical research in solid tumors such as esophageal cancer, colorectal cancer, and non-small cell lung cancer (NSCLC).

- **Xinbaizi (欣柏梓®)**

Xinbaizi receives marketing approval in June 2026, with the indication for the treatment of metastatic breast cancer after failure of combination chemotherapy or breast cancer relapse within 6 months of adjuvant chemotherapy. Phase III clinical study demonstrated that the Xinbaizi achieves a significant improvement in efficacy compared to conventional paclitaxel albumin, with an ORR increase of 10% (35.8% vs 25.8%) and, a significant prolongation of mPFS by 1.5 months (8.31 months vs 6.83 months), while mOS has not yet been reached, with a 33% reduction in the risk of death (HR=0.67), confirming clear survival benefits for patients.

In the first half of 2026, sales revenue of this therapeutic area recorded a slight year-on-year decline of 4.3%. The sales revenue of Duoenyi (多恩益®) experienced a significant year-on-year decline due to the impact of the price reduction under NRDL. Benefiting from the communication of the product’s evidence-based advantages and the steady increase in clinical penetration of the long-acting white blood cell booster regimen, the sales revenue of Jinyouli (津優力®) recorded a substantial year-on-year growth; and the sales revenue of Duoenda (多恩達®) and Enshuxing (恩舒幸®) maintained stable growth.

Management Discussion and Analysis

Anti-infectives

Major products include Anfulike (安復利克®) (amphotericin B cholesteryl sulfate complex for injection), Ansulike (安速利克®) (amphotericin B liposome for injection), Weihong (維宏®) (azithromycin tablets/capsules/enteric tablets, azithromycin for injection), Shuluoke (舒羅克®) (meropenem for injection), Nuomoling (諾莫靈®) (amoxicillin capsules), Xianqu (先曲®) (ceftriaxone sodium for injection), Xianwu (先伍®) (cefazolin sodium for injection) and Oujian (歐健®) (cefixime capsules), etc.

- **Anfulike (安復利克®)**

Anfulike was approved for marketing through priority review in March 2021 and included in the NRDL in the same year for the treatment of patients with invasive fungal infections. This product has undergone modifications of lipid structure, which significantly reduce the incidence of nephrotoxicity and hypokalaemia, expand the applicable population, and help lower the medical cost. Recognised for its clinical value and market demand, Anfulike is jointly recommended by the Ministry of Industry and Information Technology and the National Health Commission of the People's Republic of China as a “clinically urgent, market-deficient” drug.

- **Ansulike (安速利克®)**

Ansulike was approved for marketing in September 2024. As a polyene antibiotic, it is one of the most potent and broad-spectrum drugs for the prevention and treatment of invasive fungal diseases. Utilising a liposomal drug delivery system, it encapsulates amphotericin B in small unilamellar liposomes (less than 100nm) composed of hydrogenated soybean phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Ansulike is the first amphotericin B liposome in the PRC to pass the consistency evaluation. In 2025, it was successfully included in the NRDL through price negotiation, with all reimbursement restrictions removed. The updated reimbursement policy was implemented in January 2026, benefiting more antifungal patients. It was approved for marketing in the European Union in April 2026, marking a “zero breakthrough” for Chinese liposome preparations in the European market.

In the first half of 2026, the sales revenue of Ansulike (安速利克®) and Weihong (維宏®) recorded significant year-on-year growth. The sales revenue of Anfulike (安復利克®), Shuluoke (舒羅克®) and Nuomoling (諾莫靈®) remained stable. The sales revenue of Oujian (歐健®) and Xianqu (先曲®) experienced a year-on-year decline due to market competition and centralised procurement.

Cardiovascular

Major products include Xuanning (玄寧®) (maleate levamlodipine tablets/dispersible tablets), Encun (恩存®) (clopidogrel bisulfate tablets), Abikang (阿比康®) (aspirin enteric tablets), Yishuning (意舒寧®) (nifedipine controlled-release tablets), Mingfule (明復樂®) (recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA)), Daxinning (達新寧®) (dronedarone hydrochloride tablets) and Meiluolin (美洛林®) (ticagrelor tablets), etc.

- **Xuanning (玄寧®)**

Xuanning is mainly used for the treatment of hypertension and angina (including chronic stable angina and vasospastic angina), and is a product in the NRDL and National Essential Medicines List. The Group will continue to implement all-channel promotion strategy, strengthen penetration into lower-tier markets and patient transition in and outside hospitals. At the same time, the Group will enhance promotion in retail terminals and online platform, so as to fully unleash the brand advantage of the product and increase the accessibility and medication coverage.

Management Discussion and Analysis

- **Encun (恩存®)**

Encun is a platelet aggregation inhibitor, which is mainly used to prevent atherosclerotic thrombotic events such as myocardial infarction and ischemic stroke. As the first domestically produced clopidogrel that has obtained the U.S. FDA approval, Encun adopts similar process and production lines to those in the U.S. market, achieving simultaneous launch in China and the U.S.. It is also the preferred antithrombotic drug for acute coronary syndrome (ACS) and preferred antiplatelet drug for stroke prevention recommended by authoritative domestic and international guidelines and consensus. Leveraging stringent quality control and international certification, Encun rapidly iterated domestically and its sales volume ranked second only to the originator drug, and led other domestic competitors. Meanwhile, it successfully entered overseas markets such as the U.S., becoming a model for the internationalisation of domestic cardiovascular drugs. In the future, leveraging the international certification and market advantage of Encun, the Company will deepen the cooperation with overseas pharmaceutical companies as well as continue to consolidate and enhance its competitive strength in domestic and global markets.

- **Mingfule (明復樂®)**

Mingfule is a domestic innovative third-generation specific thrombolytic drug independently developed by the Group based on the Chinese genome sequence, focusing on the thrombolysis treatment in patients with acute myocardial infarction within 6 hours of onset. With its outstanding efficacy and favorable safety, Mingfule is a preferred thrombolytic drug recommended by multiple authoritative guidelines, including the Guidelines for the Rational Medication for Thrombolytic Treatment of Acute ST-Segment Elevation Myocardial Infarction (2nd Edition), Chinese Expert Consensus on Microcirculation Protection Strategies for Emergency PCI in Patients with ST-Segment Elevation Myocardial Infarction, Chinese Expert Consensus on Pre-hospital Thrombolysis for ST-Segment Elevation Acute Myocardial Infarction and Expert Consensus on Intracoronary Thrombolysis during Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction (2025). Considering its clinical advantages in cardiovascular emergency care, Mingfule has become an important therapeutic option in this field.

In the first half of 2026, the sales revenue of Xuanning (玄寧®), Encun (恩存®), and Daxinning (達新寧®) maintained steady year-on-year growth; whereas the sales revenue of Meiluolin (美洛林®) and Abikang (阿比康®) experienced a certain degree of year-on-year decline due to market competition and the impact of centralised volume-based procurement.

Respiratory System

Major products include Yiluoda (伊絡達®) (nintedanib soft capsules), Enyitan (恩益坦®) (omalizumab for injection), Qixin (琦昕®) (oseltamivir phosphate capsules), Nuoyian (諾一安®) (montelukast sodium tablets/chewable tablets), Qixiao (琦效®) (arbidol hydrochloride tablets), Zhongnuo Like (中諾立克®) (ambroxol hydrochloride oral solution) and Zhongnuoping (中諾平®) (ambroxol hydrochloride extended-release tablets), etc.

- **Yiluoda (伊絡達®)**

Yiluoda is the first generic nintedanib preparation in China, indicated for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD), progressive fibrosing interstitial lung diseases (PF-ILD) and idiopathic pulmonary fibrosis (IPF). Currently, all three of the aforementioned indications have been included in the NRDL, providing strong support for the robust growth of the product.

Management Discussion and Analysis

- **Enyitan (恩益坦®)**

Enyitan is the first biosimilar drug of Xolair (茁樂®) developed as Class 3.3 therapeutic biological product in China. It is indicated for adults and adolescents (12 years of age and older) with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. In February 2025, Enyitan received approval for the new indication of moderate to severe persistent allergic asthma. The Global Strategy for Asthma Management and Prevention (GINA 2024) report states that for patients 6 years of age and older with severe allergic asthma, IgE therapy (such as omalizumab) is strongly recommended. The clinical equivalence of Enyitan with the original drug has been verified through rigorous head-to-head clinical studies. Following its market launch, it was rapidly incorporated into the recommended treatment pathways of the China Guidelines for the Diagnosis and Treatment of Allergic Asthma (2025 Edition) and the Guidelines for the Diagnosis and Treatment of Chronic Spontaneous Urticaria, and was included in the NRDL in 2025 at the same time.

In the first half of 2026, affected by the centralised volume-based procurement and the market condition, the sales revenue of Yiluoda (伊絡達®) and Nuoyian (諾一安®) experienced a decline year-on-year. The sales revenue of Enyitan (恩益坦®) achieved substantial year-on-year growth by expanding policies such as terminals and dual-channel access.

Digestion and Metabolism

Major products include Shuanglexin (雙樂欣®) (metformin hydrochloride tablets/extended-release tablets), Oubeituo (歐倍妥®) (esomeprazole magnesium enteric-coated capsules), Debixin (得必欣®) (omeprazole enteric-coated capsules/tablets/injection), ilaprazole enteric-coated tablets, Xinweiping (欣維平®) (acarbose tablets) and Linmeixin (林美欣®) (glimepiride dispersible tablets).

- **Oubeituo (歐倍妥®)**

Oubeituo is the S-isomer of omeprazole, a core proton pump inhibitor (PPI) with a more potent acid-suppressing effect and higher bioavailability. This product is consistently recommended by authoritative domestic and international guidelines as the drug of choice for the treatment of gastro-esophageal reflux disease and peptic ulcers. It can also be used in combination with antibiotics for *Helicobacter pylori* (Hp) eradication therapy. Having passed consistency evaluation and obtained the U.S. FDA certification, Oubeituo delivers originator-level quality while significantly reducing patient burden. It stands as a preferred medication for its potent efficacy, rapid onset of action, and suitability for both initial and long-term maintenance therapy.

- **Debixin (得必欣®)**

Debixin, a classic PPI, is included in the National Essential Medicines List and classified as Category A under the medical insurance. Recommended by numerous domestic and international authoritative guidelines, it is indicated for the treatment of various gastric diseases caused by excessive gastric acid.

In the first half of 2026, the sales revenue of Xinweiping and Debixin maintained stable growth, while Oubeituo experienced a year-on-year decline.

Management Discussion and Analysis

Other Therapeutic Areas

Major products include Youdening (優得寧®) (Celecoxib Capsules), Qimaite (奇邁特®) (tramadol hydrochloride tablets), Ouwei (歐維®) (mecobalamin tablets), Sodium Chloride Injection, Gaoshunsong (高順松®) (Acemetacin Sustained-Release Capsules), Lidocaine Hydrochloride Injection, Gubang (固邦®) (alendronate sodium tablets/enteric tablets) and so on.

Bulk Product Business

In the first half of 2026, the bulk product business recorded sales revenue of RMB1,660 million, representing a year-on-year decrease of 20.0%.

Vitamin C

In the first half of 2026, the sales revenue of Vitamin C products amounted to RMB1,010 million, representing a decrease of 15.5% as compared with the same period last year. The decrease in revenue was primarily due to a decline in product selling prices. Meanwhile, the release of industry capacity resulted in increased supply and intensified competition, driving down overall market price. The Group will keep on consolidating product quality, enhancing customer services, steadily expanding overseas sales channels, and continuously increasing its market share.

Antibiotics

In the first half of 2026, the sales revenue of antibiotics amounted to RMB650 million, representing a decrease of 26.0% as compared with the same period last year. The decrease was mainly due to the intensified market competition and the effect of downstream products being selected in the 11th batch of the national volume-based procurement, which led to a decline in both sales volume and prices of penicillin-series products and 7-ACA, as well as a certain degree of decline in sales volume of penem-series products.

FUNCTIONAL FOOD AND OTHER BUSINESSES

In the first half of 2026, the functional food and other businesses recorded sales revenue of RMB873 million, representing a decrease of 8.2% as compared with the same period last year, mainly due to the decrease in both sales volume and prices of anhydrous glucose and caffeine during the period.

RESEARCH AND DEVELOPMENT

R&D expenses for the period increased by 12.9% to RMB3,029 million as compared with the same period last year, accounting for 29.8% of the revenue from the finished drug business (excluding the impact of licence fee income). Currently, there are over 130 products in various clinical R&D stages, with 16 of them having submitted applications for marketing approval and nearly 30 key products in the registration stage of clinical trials.

Management Discussion and Analysis

REGULATORY UPDATES

Since the beginning of 2026, the regulatory progress of the Group in the PRC is as follows: 6 innovative drugs have obtained marketing approvals; applications for marketing approval of 9 drugs have been accepted; 3 drugs have been granted breakthrough therapy designations; 21 drugs have obtained clinical trial approvals. In addition, the Group received 9 clinical trial approvals in overseas markets and received marketing approval in the European Union for one drug developed in-house.

China

Marketing Approvals Obtained

Month	Drug Candidate	Indication
January 2026	Clevidipine injectable emulsion	Treatment of patients with hypertension when oral therapy is not feasible or is anticipated to be ineffective
March 2026	Aprepitant injection	Prevention of postoperative nausea and vomiting (PONV) in adults
May 2026	Ustekinumab injection	It is indicated for the treatment of adults with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant of other systemic therapies, including ciclosporin and methotrexate (MTX), or PUVA (psoralen and ultraviolet A), and for the treatment of patients aged 6 years and older with moderate to severe plaque psoriasis, weighing 60 kg to 100 kg, who have had an inadequate response to, or are intolerant of, other systemic therapies or phototherapy
May 2026	Anbenitamab injection	In combination with chemotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one prior treatment regimen containing trastuzumab
June 2026	Paclitaxel for injection (albumin-bound) (II)	The treatment of metastatic breast cancer after failure of chemotherapy or breast cancer relapse within 6 months of adjuvant chemotherapy (prior chemotherapy regimens should have included an anthracycline unless clinically contraindicated)
July 2026	Paliperidone palmitate injection	The treatment of schizophrenia in both acute and maintenance phases

Management Discussion and Analysis

Applications for Marketing Approval Accepted

Month	Drug Candidate	Indication
January 2026	Prusogliptin and metformin extended-release tablets	An adjunct to diet and exercise for adult patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on metformin monotherapy or who are already receiving combination therapy with prusogliptin and metformin
May 2026	Sitagliptin and metformin extended-release tablets	Type 2 diabetes
May 2026	Dextromethorphan bupropion extended-release tablets	Depression in adults
June 2026	SYH9056 tablets (Valsartan and Levamlodipine Maleate Tablets)	Mild-to-moderate essential hypertension inadequately controlled by monotherapy
June 2026	Secukinumab injection	Moderate-to-severe plaque psoriasis, among others
June 2026	Edaglutide Alfa injection	Glycaemic control in adults with type 2 diabetes
July 2026	Trastuzumab envedotin injection	Unresectable or metastatic HER2-positive breast cancer in adult patients who have received one or more prior anti-HER2 therapies
July 2026	Sirolimus for injection (albumin-bound)	Unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumour (PEComa)
August 2026	Anbenitamab injection (KN026)/docetaxel for injection (albumin-bound) (HB1801)	Adult patients with early-stage or locally advanced HER2-positive breast cancer receiving neoadjuvant therapy

Breakthrough Therapy Designations (BTD) Granted

Month	Drug Candidate	Indication
May 2026	SYS6010	Unresectable locally advanced or metastatic esophageal squamous cell carcinoma that has failed prior first-line treatment with a platinum-containing chemotherapy regimen and an immune checkpoint inhibitor (ICI)
July 2026	Docetaxel for injection (albumin-bound) (HB1801)/anbenitamab injection (KN026)	In combination with docetaxel (albumin-bound) for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
July 2026	SYS6043	Monotherapy for the treatment of platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer

Management Discussion and Analysis

Clinical Trial Approvals Obtained

First Indication

Month	Drug Candidate	Indication
January 2026	SYS6055 injection	Relapsed/refractory aggressive B-cell lymphoma
February 2026	SYH9089 injection (ropivacaine long-acting injection)	Post-operative analgesia
March 2026	SYS6053 (emicizumab injection)	Treatment of patients with Hemophilia A
March 2026	Indacaterol Acetate and Mometasone Furoate Powder for Inhalation	Maintenance treatment of asthma in adults and adolescents 12 years of age and older
March 2026	SYH2059 powder for inhalation (a highly selective PDE4B inhibitor)	Interstitial lung disease
March 2026	SYH2082 injection (GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection)	Weight management for individuals with obesity or overweight and at least one weight-related comorbidity
March 2026	JMT205 injection (nirsevimab injection)	Prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season
April 2026	SYS6051 for injection (TF ADC)	Advanced solid tumors
May 2026	SYH2095 tablets (a highly selective KAT6 inhibitor)	Advanced malignant tumors
June 2026	SYS6063 injection (mRNA-LNP-based bispecific CD19 and BCMA CAR-T cell injection)	Relapsed/refractory systemic lupus erythematosus
July 2026	SYS6052 (recombinant herpes zoster vaccine)	Prevention of herpes zoster
July 2026	SYS6067 injection	For use in patients with non-myeloid malignant tumors to reduce the incidence of infections manifested by febrile neutropenia when receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia
July 2026	SYS6057 injection	Prevention of lower respiratory tract disease caused by recombinant respiratory syncytial virus (RSV) infection

Management Discussion and Analysis

Additional Indication

Month	Drug Candidate	Indication
January 2026	SYS6090 injection (PD-1/IL-15)	For the treatment of locally advanced (phase IIIB/IIIC), metastatic (phase IV) NSCLC and extensive-phase SCLC that are not amenable to curative treatment (not suitable for complete surgical resection with curative intent or chemoradiotherapy)
February 2026	SYS6023 for injection (HER3 ADC)	In combination with other drugs for the treatment of unresectable locally advanced or metastatic breast cancer
March 2026	JMT206 injection (ACTR-IIA/IIIB)	Sarcopenia
March 2026	SYS6090 injection (PD-1/IL-15)	Digestive system tumors
April 2026	SYS6006 injection	Advanced solid tumors
April 2026	SYH2069 injection (GLP-1/GIP receptor dual-biased agonist)	As a medication adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
June 2026	SYS6041 for injection	In combination with other drugs for the treatment of ovarian cancer
June 2026	SYS6010 for injection	Adjuvant therapy for NSCLC in combination with enlonstobart

Management Discussion and Analysis

Overseas

Clinical Trial Approvals Granted by the U.S. FDA

Month	Drug Candidate	Indication
January 2026	SYH2072 tablets (potent aldosterone synthase inhibitor)	Uncontrolled hypertension and resistant hypertension
February 2026	SYH2082 injection (GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection)	Weight management for individuals with obesity or overweight and at least one weight-related comorbidity
February 2026	Paclitaxel protein-bound particles for injectable suspension, rapid suspension (albumin-bound)	Metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy
March 2026	SYH2059 powder for inhalation (a highly selective PDE4B inhibitor)	Pulmonary fibrosis (PF)
April 2026	SYS6036	Advanced solid tumors
April 2026	SYH2095 tablets (a highly selective KAT6 inhibitor)	Advanced malignant tumors
April 2026	SYS6051 for injection (TF ADC)	Advanced solid tumors
June 2026	SYH9017 (semaglutide long-acting injection)	Weight management in adults who are overweight or obese, along with a reduced-calorie diet and increased physical activity
June 2026	SYHX2008 (octreotide long-acting injection)	Acromegaly

Marketing authorisation approved in Europe

Month	Drug Candidate	Indication
April 2026	Amphotericin B liposomal, powder for concentrate for dispersion for infusion	Systemic and/or deep fungal infections affecting one or more of the body's internal organs, and empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad-spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause

Management Discussion and Analysis

REGISTRATION APPROVALS OBTAINED

Since the beginning of 2026, a total of 5 generic drugs have obtained drug registration approvals, namely budesonide enteric-coated capsules, lansoprazole enteric-coated capsules, iron sucrose injection, brexpiprazole, empagliflozin and metformin extended-release tablets.

Major Clinical Trial Progress During the Reporting Period

Initiation of Pivotal Clinical Trial

Octreotide long-acting injection

- In May 2026, the first site was initiated in the Phase III clinical trial conducted in China of Octreotide long-acting injection for the treatment of acromegaly.

CM326 injection

- In January 2026, the first site was initiated in the Phase III clinical trial conducted in China of CM326 injection for the treatment of moderate-to-severe asthma.
- In February 2026, the first site was initiated in the Phase III clinical trial conducted in China of CM326 injection for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).

Anbenitamab repodatecan (JSKN003)

- In February 2026, the first site was initiated in the Phase III clinical trial conducted in China evaluating Anbenitamab repodatecan for the treatment of third-line HER2-positive advanced colorectal cancer.

Anbenitamab injection (KN026)

- In February 2026, the first site was initiated in the Phase III clinical trial conducted in China of anbenitamab injection in combination with docetaxel (albumin-bound) and chemotherapy for the neoadjuvant treatment of HER2-positive breast cancer.

SYH2053 injection (PCSK9 SiRNA)

- In February 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYH2053 injection in combination with statins for the treatment of primary hypercholesterolemia and mixed dyslipidemia.
- In February 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYH2053 injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia.
- In March 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYH2053 injection in combination with statins for the treatment of heterozygous familial hypercholesterolemia.

Paclitaxel cationic liposome for injection

- In March 2026, Phase III stage was achieved and the first site was initiated in the Phase Ib/III clinical trial conducted in China of combination systemic therapy for first-line treatment of colorectal cancer liver metastases.

Management Discussion and Analysis

SYS6010 (EGFR ADC)

- In March 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6010 for injection comparing investigator's choice of chemotherapy for the treatment of 2L esophageal squamous cell carcinoma.
- In March 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6010 for injection comparing docetaxel for the treatment of 2L driver gene-negative non-squamous non-small cell lung cancer (NSCLC).
- In March 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6010 for injection comparing investigator's choice of chemotherapy for the treatment of HER2-negative, EGFR-positive breast cancer.
- In June 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6010 for injection in combination with enlonstobart for the adjuvant treatment of NSCLC.
- In June 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6010 for injection for the first-line treatment of driver gene-negative PD-L1-positive NSCLC.

SYHA1813 oral solution

- In May 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYHA1813 oral solution for the treatment of recurrent or progressive high-grade meningiomas.

Bempedoic acid tablets

- In June 2026, the first site was initiated in the Phase III clinical trial conducted in China of bempedoic acid tablets in combination with statins for hyperlipidemia.

Aprocitentan tablets

- In June 2026, the first site was initiated in the Phase III clinical trial conducted in China of aprocitentan tablets for the treatment of refractory hypertension.

SYS6043 for injection

- In July 2026, the first site was initiated in the Phase III clinical trial conducted in China of SYS6043 for injection comparing investigator's choice of chemotherapy for the treatment of platinum-resistant ovarian cancer.

Last Subject Enrollment of Pivotal Clinical Trials

SYS6010 (EGFR ADC)

- In February 2026, the last subject was enrolled in the Phase III clinical trial conducted in China of SYS6010 for injection comparing platinum-based chemotherapy for the treatment of second-line EGFR-mutated NSCLC.

Prusogliptin tablets (in combination)

- In March 2026, the last subject was enrolled in the Phase III clinical trial conducted in China in combination with dapagliflozin and metformin for the treatment of type 2 diabetes mellitus.

Ammuxetine hydrochloride enteric-coated tablets

- In April 2026, the last subject was enrolled in the Phase III clinical trial conducted in China of ammuxetine hydrochloride enteric-coated tablets for the treatment of depression.

Management Discussion and Analysis

SYH2053 injection (PCSK9 SiRNA)

- In April 2026, the last subject was enrolled in the Phase III clinical trial conducted in China of SYH2053 injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia.
- In May 2026, the last subject was enrolled in the Phase III clinical trial conducted in China of SYH2053 injection in combination with statins for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

SYHX1901 tablets

- In April 2026, the last subject was enrolled in the Phase III clinical trial initiated in China of SYHX1901 tablets for the treatment of moderate-to-severe plaque psoriasis.

JMT101 injection

- In May 2026, the last subject was enrolled in the Phase III clinical trial of JMT101 injection in combination with osimertinib for the treatment of first-line EGFR classical mutated NSCLC.

Statistical Analysis Results of Pivotal Clinical Trials

Anbenitamab injection (KN026)

- In April 2026, the TFLs were finalised for the Phase III clinical trial conducted in China of anbenitamab injection in combination with docetaxel (albumin-bound) compared with trastuzumab and pertuzumab in combination with docetaxel injection for the neoadjuvant treatment of HER2-positive breast cancer, with the results meeting expectations.
- In June 2026, the Phase III clinical trial conducted in China of anbenitamab injection in combination with docetaxel (albumin-bound) compared with trastuzumab and pertuzumab in combination with docetaxel injection for the first-line treatment of HER2-positive advanced breast cancer met its primary endpoint in a pre-specified interim analysis.

Secukinumab injection

- In January 2026, the clinical trial summary report was completed for the Phase III clinical study conducted in China of secukinumab injection for the treatment of moderate-to-severe plaque psoriasis.

Dextromethorphan bupropion extended-release tablets

- In March 2026, the clinical trial summary report was finalised for the Phase III clinical trial conducted in China of dextromethorphan bupropion extended-release tablets for the treatment of adult depression.

TG103 injection (GLP-1 receptor agonists)

- In February 2026, the TFLs were finalised for the Phase III clinical trial conducted in China of TG103 injection for the treatment of type 2 diabetes, with the results meeting expectations.
- In February 2026, the TFLs were finalised for the Phase III clinical trial conducted in China of TG103 injection in combination with metformin for the treatment of type 2 diabetes mellitus, with the results meeting expectations.

Management Discussion and Analysis

Valsartan levoamlodipine maleate tablets

- In April 2026, the TFLs were finalised for the Phase III clinical trial conducted in China for the treatment of primary mild and moderate hypertension that cannot be effectively controlled by monotherapy, with the results meeting expectations.

Ammuxetine hydrochloride enteric-coated tablets

- In July 2026, the Phase III clinical trial conducted in China of ammuxetine hydrochloride enteric-coated tablets for the treatment of depression achieved its primary endpoint.

Sirolimus for injection (albumin-bound)

- In April 2026, the Phase Ib/III clinical trial conducted in China of sirolimus for injection (albumin-bound) comparing investigator's choice for the treatment of advanced malignant PEComa met its primary endpoint.

Publication of Major Results

Product	Study Title	Journals/Meetings
JMT101	JMT101 + Real world study for oxetinib	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — poster presentation
	JMT101 injection — in combination with oxetinib — ≥ 2L EGFR Ex20 ins NSCLC-Phase II	2026 European Lung Cancer Congress (ELCC) — oral presentation
ALMB-0168	Case report	Antibody Therapeutic (IF: 4.5)
SYS6010	Phase I clinical trial of SYS6010 for the treatment of advanced solid tumors — (nasopharyngeal cancer data)	2026 American Association for Cancer Research (AACR) Annual Meeting — invited oral presentation
	SYS6010 in combination with SG001 ± chemotherapy — first-line treatment of advanced NSCLC and other solid tumors — Phase I/II — (esophageal cancer data)	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — online presentation
	SYS6010 — advanced solid tumors — Phase II (esophageal cancer data)	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — poster presentation
	SYS6010 + SYH2051 ± bevacizumab versus SYS6010 — advanced solid tumors — Phase Ib/II — gastric cancer data	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — poster presentation
	SYS6010 + SG001 –advanced lung cancer cohort — Phase II programme	2026 World Conference on Lung Cancer (WCLC) — oral presentation
	SYS6010-001 — advanced solid tumour — Phase I (NSCLC data)	Cancer Cell (IF: 56.1)
Paclitaxel cationic liposome	IIT clinical trial of paclitaxel cationic liposome for the treatment of patients with advanced solid tumors (intra-arterial chemotherapy)	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — online presentation

Management Discussion and Analysis

Product	Study Title	Journals/Meetings
Anbenitamab injection (KN026)/ docetaxel (albumin-bound)	Anbenitamab injection — gastric cancer — Phase III clinical trial	Annals of Oncology IF: 65.4
	KN026 + docetaxel versus trastuzumab + pertuzumab + docetaxel — 1L HER2- positive recurrent and metastatic breast cancer — Phase III	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — oral presentation
		JAMA Oncology (IF: 23.9) — accepted
Irinotecan liposome injection	Irinotecan liposome — 1L pancreatic cancer — Phase II clinical trial	Nature Communications (IF: 14.7)
SYS6002	SYS6002-001 — advanced solid tumors — Phase I urothelial carcinoma	2026 American Society of Clinical Oncology (ASCO) Annual Meeting — poster presentation
	Advanced solid tumor — Phase I programme — cervical cancer	2026 International Gynecologic Cancer Society (IGCS) Annual Meeting — rapid oral presentation
SYS6043	SYS6043 — Phase I trial for advanced solid tumors	2026 Society of Gynecologic Oncology (SGO) — scientific invited oral presentation
		2026 American Society of Clinical Oncology (ASCO) Annual Meeting — oral presentation
		2026 10th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO) — oral presentation (LBA Proffered paper)
		2026 The 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) — oral presentation
	SYS6043 — Phase I trial for breast cancer	2026 European Society for Medical Oncology Congress (ESMO) — rapid oral presentation
ADC-2419	Non-clinical study	2026 American Association for Cancer Research (AACR) Annual Meeting — poster presentation
SYS6090	Non-clinical study	2026 American Association for Cancer Research (AACR) Annual Meeting — poster presentation
	Advanced solid tumors — Phase I	2026 European Society for Medical Oncology Congress (ESMO) — rapid oral presentation
SYS6023	SYS6023-001 — SYS6023 for injection — advanced solid tumours (non-small cell lung cancer) — Phase I/IIa	2026 European Society for Medical Oncology Congress (ESMO) — poster presentation
JSKN003	JSKN003-003 — JSKN003 for injection — combination therapy — 1L and perioperative HER2-positive gastric cancer — Phase II	2026 European Society for Medical Oncology Congress (ESMO) — poster presentation

Management Discussion and Analysis

Product	Study Title	Journals/Meetings
Sirolimus for injection (albumin-bound)	PEComa — Phase Ib/III project	2026 European Society for Medical Oncology Congress (ESMO) — poster presentation
Docetaxel for injection (albumin-bound)	Combined chemoradiotherapy — oesophageal cancer — Phase II project	2026 American Society for Radiation Oncology (ASTRO) — poster presentation
	Docetaxel for injection (albumin-bound) — in combination with FOLFOX vs. FOLFOX — 1L advanced gastric cancer — Phase Ib/III	2026 European Society for Medical Oncology Congress (ESMO) — poster presentation
SYH2053	Hypercholesterolemia — Phase II project	2026 European Society of Cardiology (ESC) — poster presentation
TG103 injection (Efmedaglutide alfa injection)	TG103 combination therapy — type 2 diabetes — Phase III	2026 European Association for the Study of Diabetes (EASD) — short oral presentation
CM326	Moderate to severe asthma — Phase II project	2026 European Respiratory Society (ERS) Congress — poster presentation
Paclitaxel for injection (albumin-bound) (II)	A multicenter, randomised, double-blind, Phase III clinical trial of albumin-bound paclitaxel (SYHX2011) in patients with advanced breast cancer	Cancer Communications (IF: 24.9)
ALMB-0166	ALMB-0166 — spinal cord injury — Phase I	Brain Communications (IF: 4.5)
HF114-006	Amphotericin B cholesteryl sulfate complex for injection — invasive candidiasis and invasive aspergillosis — Phase III	Scientific Reports (IF: 4.9) — accepted
SYH2092	Non-clinical study	2026 European Congress on Obesity (ECO) — abstract

PATENT DATA

From January 2026 to July 2026, the Group filed a total of 54 PCT international patent applications and 507 patent applications (170 domestic and 337 foreign). In addition, the Group was granted 44 patents (15 domestic and 29 foreign).

As at 31 July 2026, the Group filed a total of 315 PCT international patent applications and 3,063 patent applications (1,781 domestic and 1,282 foreign). In addition, the Group was granted 1,098 patents (685 domestic and 413 foreign) in aggregate.

BUSINESS DEVELOPMENT

The Group continues to strengthen its internal innovation capabilities, with R&D investment increasing year by year. To date, it has established a robust R&D pipeline and accumulated a number of high-quality innovative assets. In recent years, we have actively pursued the international expansion of our R&D pipeline and accelerated the global translation of innovative outcomes through out-licensing of innovative products and strategic collaborations with multinational pharmaceutical companies.

Management Discussion and Analysis

OUT-LICENSING

Sustained-Release Drug Delivery Technology Platform and AI-driven Peptide Drug Discovery Platform

In January 2026, the Group entered into a strategic collaboration and licence agreement with AstraZeneca for the development of innovative long-acting peptide medicines, utilising the Group's sustained-release delivery technology platform and AI-driven peptide drug discovery platform. AstraZeneca has been granted exclusive global rights (excluding the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan) to its portfolio of once-monthly injectable weight management products. The Group will receive an upfront payment of US\$1.2 billion and is also eligible to receive up to US\$3.5 billion in potential research and development milestone payments and up to US\$13.8 billion in potential sales milestone payments, plus up to double-digit tiered royalties.

The Group received the US\$1.2 billion upfront payment under the agreement on 29 May 2026, and a US\$25 million R&D milestone payment on 10 July 2026, indicating that the relevant R&D work is progressing steadily as planned.

siRNA Drug Discovery Platform

In July 2026, the Group entered into a collaboration, option and licence agreement with AstraZeneca to co-develop novel small nucleic acid drug candidates leveraging the Group's siRNA drug discovery platform and extrahepatic targeted delivery platform. The parties will conduct R&D on pre-clinical candidates for two targets with potential to treat multiple indications of renal diseases; AstraZeneca will have the right to exercise its option to obtain the rights for development, manufacturing and commercialisation on a worldwide basis or outside the PRC, as applicable. The Group will receive an upfront payment of US\$30 million, and is also entitled to receive up to US\$540 million in potential R&D milestone payments and up to US\$1,200 million in potential sales milestone payments, plus single-digit percentage royalties.

The Group received the upfront payment of US\$30 million under the agreement on 12 August 2026. The receipt of this upfront payment marks the smooth advancement of the collaboration between both parties, benefiting the overall strategic layout of the Group and accelerating the development of the small nucleic acid pipeline.

ESTABLISHMENT OF A JOINT VENTURE

In August 2026, the Group and AstraZeneca entered into a joint venture contract to establish a joint venture for the construction of a new-generation biologics manufacturing facility in Shijiazhuang, China (the "Joint Venture"). The Joint Venture aims to combine the Group's AI-driven Good Manufacturing Practice (GMP) system and pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management, with a commitment to delivering high-quality medicines to patients worldwide. The Group and AstraZeneca will contribute capital at an equity ratio of 51% and 49%, respectively, and will jointly manage the construction and day-to-day operations of the Joint Venture by leveraging their respective expertise. The joint establishment of the Joint Venture by both parties will help integrate the Group's advantages in building highly automated, intelligent, and lean manufacturing facilities and current Good Manufacturing Practice (cGMP) operations with AstraZeneca's global quality system and supply management experience, thereby creating high-quality manufacturing capabilities that meet the demands of the international market.

FINANCIAL REVIEW

FINANCIAL RESULTS

Revenue and Gross Profit Margin

Revenue for the first half of 2026 amounted to RMB18,594 million, an increase of 40.1% as compared with RMB13,273 million in the first half of 2025. The increase was mainly due to an increase in licence fee income and revenue from sale of finished drug during the period. Gross profit margin for the period increased by 10.6 percentage points to 76.2% as compared with the same period last year, mainly due to the increase in the proportion of revenue from the finished drug business.

Other Income

Other income for the first half of 2026 amounted to RMB309 million (first half of 2025: RMB419 million), mainly consisting of interest income on bank deposits and balances of RMB92 million (first half of 2025: RMB100 million) and government grant income of RMB88 million (first half of 2025: RMB143 million).

Other Gains or Losses, Net

A net loss of RMB80 million was reported in the first half of 2026 (first half of 2025: net gain of RMB185 million), mainly consisting of fair value gain on financial assets measured at FVTPL of RMB34 million (first half of 2025: gain of RMB165 million), net foreign exchange loss of RMB137 million (first half of 2025: net gain of RMB17 million) and fair value gain on structured bank deposits of RMB18 million (first half of 2025: gain of RMB17 million).

Operating Expenses

Selling and distribution expenses for the first half of 2026 amounted to RMB3,291 million, an increase of 7.9% as compared with RMB3,049 million in the first half of 2025, primarily due to an increase in employee share-based compensation expenses and active promotion of newly launched products during the period.

Administrative expenses for the first half of 2026 amounted to RMB488 million, an increase of 21.4% as compared with RMB402 million in the first half of 2025, and the increase was mainly due to an increase in employee share-based compensation expenses.

R&D expenses for the first half of 2026 amounted to RMB3,029 million, an increase of 12.9% as compared with RMB2,683 million in the first half of 2025, which was primarily attributable to the steady increase in spending on ongoing and newly initiated clinical trials.

Income Tax Expense

Income tax expense for the first half of 2026 amounted to RMB1,069 million (first half of 2025: RMB544 million), which represented provision of income tax expense based on the taxable profit of the subsidiaries and PRC withholding tax on dividend distributions by the subsidiaries.

NON-HKFRS ACCOUNTING STANDARDS MEASURE

For the purpose of assessing the performance of the Group, the Company has also presented the underlying profit attributable to shareholders of the Company as an additional financial measure, which is not required by or presented in accordance with the HKFRS Accounting Standards. The Group believes that this non-HKFRS Accounting Standards measure better reflects the underlying operational performance by eliminating certain non-operating items that are not considered indicative of its operational performance. However, the presentation of this non-HKFRS Accounting Standards measure is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with HKFRS Accounting Standards.

Additional information is provided below to reconcile the reported and underlying profit attributable to shareholders of the Company:

	Six months ended 30 June	
	2026 (RMB'000)	2025 (RMB'000)
Reported profit attributable to shareholders of the Company	6,094,212	2,547,851
Adjustments for:		
— Fair value gain on financial assets measured at FVTPL (<i>note a</i>)	(34,418)	(164,591)
— Recognition of/(reversal of) employee share-based compensation expenses (<i>note b</i>)	115,323	(72,010)
— Effect of corresponding income tax	(10,838)	8,271
Underlying profit attributable to shareholders of the Company	6,164,279	2,319,521

Notes:

- Fair value gain on financial assets measured at FVTPL arises from the measurement of the Group's investments in certain partnerships, funds and listed equity securities at fair value.
- Of the total employee share-based compensation expenses recognised during the period, RMB28,471,000 (first half of 2025: reversal of an expense of RMB72,280,000) was in respect of share awards granted to selected employees of the Group by Key Honesty Limited, a shareholder of the Company.

Management Discussion and Analysis

LIQUIDITY AND FINANCIAL POSITION

For the first half of 2026, the Group's operating activities generated a cash inflow of RMB10,890 million (first half of 2025: RMB3,187 million). Turnover days of trade receivables (ratio of balance of trade receivables to sales, inclusive of value added tax for sales in China) was 52 days, lower than 65 days in 2025, which was mainly due to the increased proportion of licence fee income during the period. The Group will continue to strengthen its control and management of accounts receivable. Turnover days of inventories (ratio of balance of inventories to cost of sales) was 121 days, lower than 126 days in 2025. Current ratio was 2.1 as at 30 June 2026, which remains stable as compared with 2.2 as at the end of 2025. Capital expenditure for the period amounted to RMB628 million, which was mainly spent to construct production facilities and improve production efficiency.

The Group's financial position remained solid. As at 30 June 2026, the Group had bank deposits, balances and cash of RMB14,177 million (31 December 2025: RMB9,481 million), structured bank deposits of RMB8,486 million (31 December 2025: RMB2,776 million) and bank borrowings of RMB403 million (31 December 2025: RMB329 million). As at 30 June 2026, gearing ratio (ratio of bank borrowings to total equity) was 1.0% (31 December 2025: 1.0%). The Group's sales revenues are denominated in Renminbi for domestic sales in China and US dollars for export sales. The Group manages its foreign exchange risks by closely monitoring its foreign exchange exposures and mitigating the impact of foreign currency fluctuations by using appropriate hedging arrangements when considered necessary.

PLEDGE OF ASSETS

As at 30 June 2026, bank deposits of approximately RMB1 million (31 December 2025: nil) have been pledged to secure short-term banking facilities.

CONTINGENT LIABILITIES

The Group did not have any material contingent liabilities as at 30 June 2026.

EMPLOYEES

The Group employed a total of 18,626 employees as at 30 June 2026, with a majority of them employed in the Chinese Mainland. The Group continues to offer competitive remuneration packages, discretionary share options, share awards and bonuses to eligible staff, based on the performance of the Group and the employee.

Report on Review of Condensed Consolidated Financial Statements

Deloitte.

德勤

TO THE BOARD OF DIRECTORS OF
CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of CSPC Pharmaceutical Group Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”) set out on pages 31 to 63, which comprise the condensed consolidated statement of financial position as of 30 June 2026 and the related condensed consolidated income statement, condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and HKAS 34 “Interim Financial Reporting” (“HKAS 34”) as issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”). The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with HKAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” as issued by the HKICPA. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with HKAS 34.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
20 August 2026

Condensed Consolidated Income Statement

For the six months ended 30 June 2026 (Unaudited)

		Six months ended 30 June	
	Notes	2026 RMB'000	2025 RMB'000
Revenue	3	18,594,494	13,273,416
Cost of sales		(4,433,878)	(4,563,224)
Gross profit		14,160,616	8,710,192
Other income		309,457	419,259
Other gains or losses, net		(79,658)	185,035
Selling and distribution expenses		(3,290,854)	(3,049,160)
Administrative expenses		(487,728)	(401,715)
Research and development expenses		(3,029,461)	(2,682,631)
Other expenses		(36,007)	(28,892)
Share of results of associates		(10,630)	(14,709)
Share of results of joint ventures		6,706	1,940
Finance costs		(13,318)	(21,652)
Profit before tax	4	7,529,123	3,117,667
Income tax expense	5	(1,068,947)	(543,617)
Profit for the period		6,460,176	2,574,050
Profit for the period attributable to:			
Owners of the Company		6,094,212	2,547,851
Non-controlling interests		365,964	26,199
		6,460,176	2,574,050
		RMB cents	RMB cents
Earnings per share	6		
— Basic		53.45	22.29
— Diluted		53.36	22.29

Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2026 (Unaudited)

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Profit for the period	6,460,176	2,574,050
Other comprehensive (expense) income:		
Item that will not be reclassified to profit or loss:		
Fair value loss on financial assets measured at fair value through other comprehensive income, net of income tax	(14,130)	(120,631)
Item that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of foreign operations	10,233	7,357
Other comprehensive expense for the period, net of income tax	(3,897)	(113,274)
Total comprehensive income for the period	6,456,279	2,460,776
Total comprehensive income for the period attributable to:		
Owners of the Company	6,090,315	2,434,577
Non-controlling interests	365,964	26,199
	6,456,279	2,460,776

Condensed Consolidated Statement of Financial Position

As at 30 June 2026 (Unaudited)

	Notes	30 June 2026 RMB'000	31 December 2025 RMB'000
Non-current assets			
Property, plant and equipment	8	12,338,247	12,153,162
Right-of-use assets	9	1,300,068	1,336,253
Investment properties		69,467	71,565
Goodwill		236,048	234,904
Intangible assets	10	2,985,272	2,774,871
Interests in associates		575,004	754,737
Interests in joint ventures		603,283	710,849
Other financial assets	11	2,138,606	2,251,276
Deferred tax assets		178,377	211,505
Deposits, prepayments and other receivables	13	566,511	556,488
Bank deposits	16	4,175,625	3,391,691
		25,166,508	24,447,301
Current assets			
Inventories		2,962,172	3,090,736
Trade receivables	12	5,389,371	4,778,867
Deposits, prepayments and other receivables	13	1,577,107	1,507,394
Bills receivables	14	1,985,069	3,580,982
Amounts due from related companies	24	334,806	343,686
Amounts due from joint ventures	24	52,264	83,468
Other financial assets	11	59,065	–
Derivative financial assets		7,990	–
Structured bank deposits	15	8,485,866	2,775,915
Bank deposits, balances and cash	16	10,001,506	6,089,565
		30,855,216	22,250,613

Condensed Consolidated Statement of Financial Position

As at 30 June 2026 (Unaudited)

	Notes	30 June 2026 RMB'000	31 December 2025 RMB'000
Current liabilities			
Trade payables	17	2,348,756	2,322,004
Other payables	18	9,916,566	5,334,111
Contract liabilities	21	640,568	662,247
Bills payables	19	355,965	653,624
Amounts due to related companies	24	210,211	305,545
Amounts due to joint ventures	24	151,811	210,788
Lease liabilities		134,624	131,693
Tax liabilities		536,889	229,131
Bank borrowings	20	128,875	328,723
		14,424,265	10,177,866
Net current assets		16,430,951	12,072,747
Total assets less current liabilities		41,597,459	36,520,048
Non-current liabilities			
Other payables	18	540,643	563,241
Contract liabilities	21	851,136	851,136
Lease liabilities		114,586	180,693
Deferred tax liabilities		385,409	374,861
Bank borrowings	20	274,406	–
		2,166,180	1,969,931
Net assets		39,431,279	34,550,117
Capital and reserves			
Share capital	22	11,061,429	11,061,429
Reserves		26,562,677	22,116,738
Equity attributable to owners of the Company		37,624,106	33,178,167
Non-controlling interests		1,807,173	1,371,950
Total equity		39,431,279	34,550,117

Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2026 (Unaudited)

	Equity attributable to owners of the Company								Equity attributable to non-controlling interests				
	Share capital RMB'000	Treasury share reserve RMB'000	Employee share-based compensation reserves RMB'000	Other reserves RMB'000 (note ii)	Statutory reserves RMB'000 (note ii)	Capital contribution reserve RMB'000 (note iii)	Translation reserve RMB'000	Accumulated profits RMB'000	Sub-total RMB'000	Employee share-based compensation reserve of a subsidiary RMB'000	Share of net assets of subsidiaries RMB'000	Sub-total RMB'000	Total RMB'000
At 1 January 2025	11,032,752	(612,041)	7,969	(4,377,302)	2,305,483	588,845	(25,091)	23,344,080	32,264,695	6,805	1,594,790	1,601,595	33,866,290
Profit for the period	-	-	-	-	-	-	-	2,547,851	2,547,851	-	26,199	26,199	2,574,050
Other comprehensive (expense) income for the period, net of income tax	-	-	-	(120,631)	-	-	7,357	-	(113,274)	-	-	-	(113,274)
Total comprehensive (expense) income for the period	-	-	-	(120,631)	-	-	7,357	2,547,851	2,434,577	-	26,199	26,199	2,460,776
Dividend recognised as distribution (note 7)	-	-	-	-	-	-	-	(1,041,345)	(1,041,345)	-	-	-	(1,041,345)
Dividends paid to non-controlling interests	-	-	-	-	-	-	-	-	-	-	(7,174)	(7,174)	(7,174)
Recognition of employee share-based compensation expense	-	-	270	-	-	(72,280)	-	-	(72,010)	-	-	-	(72,010)
Cancellation of shares repurchased	-	-	-	-	-	-	-	(277,634)	(277,634)	-	-	-	(277,634)
Acquisition of additional interests in a subsidiary	-	-	-	-	-	-	-	(61,381)	(61,381)	-	(6,373)	(6,373)	(67,754)
Exercise of share options	3,417	-	(690)	-	-	-	-	-	2,727	-	-	-	2,727
At 30 June 2025	11,036,169	(612,041)	7,549	(4,497,933)	2,305,483	516,565	(17,734)	24,511,571	33,249,629	6,805	1,607,442	1,614,247	34,863,876
At 1 January 2026	11,061,429	(752,853)	13,517	(4,527,384)	2,395,351	511,553	1,247	24,475,307	33,178,167	6,805	1,365,145	1,371,950	34,550,117
Profit for the period	-	-	-	-	-	-	-	6,094,212	6,094,212	-	365,964	365,964	6,460,176
Other comprehensive (expense) income for the period, net of income tax	-	-	-	(14,130)	-	-	10,233	-	(3,897)	-	-	-	(3,897)
Total comprehensive (expense) income for the period	-	-	-	(14,130)	-	-	10,233	6,094,212	6,090,315	-	365,964	365,964	6,456,279
Purchase of shares under share award scheme	-	(279,699)	-	-	-	-	-	-	(279,699)	-	-	-	(279,699)
Dividend recognised as distribution (note 7)	-	-	-	-	-	-	-	(1,480,000)	(1,480,000)	-	-	-	(1,480,000)
Recognition of employee share-based compensation expense	-	-	86,852	-	-	28,471	-	-	115,323	-	-	-	115,323
Acquisition of subsidiaries	-	-	-	-	-	-	-	-	-	-	69,259	69,259	69,259
At 30 June 2026	11,061,429	(1,032,552)	100,369	(4,541,514)	2,395,351	540,024	11,480	29,089,519	37,624,106	6,805	1,800,368	1,807,173	39,431,279

Notes:

- The balance in other reserves mainly included (1) an amount of RMB4,030,633,000 which represents the difference between the fair value of the deemed consideration under the reverse acquisition of RMB2,631,198,000 and the fair value of the consideration paid by the Company of RMB6,661,831,000 in the reverse acquisition on 29 October 2012; (2) and the accumulated changes in fair value of financial assets designated at fair value through other comprehensive income ("FVTOCI"); and (3) repurchase of shares of CSPC Innovation Pharmaceutical Co., Ltd., a non-wholly owned listed subsidiary of the Company, for staff share incentive purpose.
- The statutory reserves were appropriated from the profit after tax of the Company's subsidiaries in the People's Republic of China (the "PRC") under the laws and regulations of the PRC.
- The balance in capital contribution reserve mainly included the deemed contribution by CSPC Holdings Company Limited ("CHL"), which comprise (1) the difference between the carrying amount of the net assets of entities comprising Robust Sun Holdings Limited ("Robust Sun") and its subsidiaries (collectively referred to as the "Robust Sun Group") and the consideration paid to CHL and its subsidiaries during group reorganisation under Robust Sun Group in 2012; (2) the imputed interest arising on a non-interest bearing loan from CHL in 2012; (3) deemed capital contribution arising from the acquisition of CSPC Shengxue Glucose Co. Ltd. from CHL in 2016; and (4) deemed capital contribution arising from the grant of share awards to employees of the Group in 2022 by a shareholder.

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2026 (Unaudited)

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Net cash from operating activities	10,889,512	3,187,376
Net cash used in investing activities:		
Purchase of property, plant and equipment	(765,346)	(1,203,202)
Addition of right-of-use assets	(38,998)	–
Purchase of intangible assets	(289,924)	(223,810)
Purchase of other financial assets	(64,027)	(100,836)
Capital injection to an associate	(60,000)	–
Capital injection to a joint venture	–	(29,000)
Receipt of government grants	36,437	114,250
Refund of deposits paid for right-of-use assets	–	18,500
Placement of structured bank deposits	(6,245,800)	(775,000)
Placement of bank deposits	(909,111)	(690,000)
Placement of restricted and pledged deposits	(115,582)	(18,132)
Withdrawal of structured bank deposits	554,038	157,038
Withdrawal of bank deposits	731,507	400,000
Withdrawal of restricted and pledged bank deposits	9,054	50,135
Interest received	101,259	100,235
Dividend received from a joint venture	20,000	20,000
Acquisition of subsidiaries	40,467	–
Proceeds from disposal of an associate	230,000	–
Proceeds from distribution of other financial assets	138,765	58,089
Proceeds from disposal of property, plant and equipment	52,272	5,303
	(6,574,989)	(2,116,430)

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2026 (Unaudited)

	Note	Six months ended 30 June	
		2026 RMB'000	2025 RMB'000
Net cash from (used in) financing activities:			
Dividends paid to non-controlling interests		–	(7,174)
Interest on lease liabilities		(4,628)	(4,216)
Interest on bank borrowings		(1,097)	(631)
Repayment of lease liabilities		(66,173)	(73,278)
Repayment of bank borrowings		(21,000)	–
New bank borrowings raised		274,406	21,000
Advances drawn on bill receivables discounted with recourse		202,371	182,734
Repurchase of ordinary shares		–	(277,634)
Acquisition of additional interests in a subsidiary		–	(67,754)
Purchase of shares under share award scheme		(279,699)	–
Proceeds from issue of shares upon exercise of options		–	2,727
		104,180	(224,226)
Net increase in cash and cash equivalents		4,418,703	846,720
Cash and cash equivalents at 1 January		5,254,498	5,917,376
Effect of foreign exchange rate changes		(6,960)	(985)
Cash and cash equivalents at 30 June, represented by bank balances and cash	16	9,666,241	6,763,111

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

1. BASIS OF PREPARATION

CSPC Pharmaceutical Group Limited (the “Company”) is a public limited company incorporated in Hong Kong and its shares are listed on the The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The condensed consolidated financial statements have been prepared in accordance with HKAS 34 issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”) as well as with the applicable disclosure requirements of the Rules Governing the Listing of Securities on the Stock Exchange.

The financial information relating to the year ended 31 December 2025 that is included in these condensed consolidated financial statements as comparative information does not constitute the Company’s statutory annual consolidated financial statements for that year but is derived from those financial statements. Further information relating to these statutory financial statements is as follows:

The Company has delivered the financial statements for the year ended 31 December 2025 to the Registrar of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the Hong Kong Companies Ordinance.

The Company’s auditor has reported on those financial statements. The auditor’s report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under sections 406(2), 407(2) or (3) of the Hong Kong Companies Ordinance.

2. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are measured at fair values, as appropriate.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are the same as those presented in the Group’s annual financial statements for the year ended 31 December 2025.

APPLICATION OF AMENDMENTS TO HKFRS ACCOUNTING STANDARDS

In the current interim period, the Group has applied the following amendments to HKFRS Accounting Standards issued by the HKICPA, for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2026 for the preparation of the Group’s condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards — Volume 11

The application of the amendments to a HKFRS Accounting Standard in the current interim period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

3. REVENUE AND SEGMENT INFORMATION

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Sale of goods	12,699,525	12,198,749
Licence fee income	5,894,969	1,074,667
Total revenue	18,594,494	13,273,416

Information reported to executive directors, being the chief operating decision maker, for the purpose of resources allocation and assessment of segment performance focuses on types of goods delivered.

The reportable segments of the Group are as follows:

- (a) Finished drugs — research and development, manufacture and sale of pharmaceutical products and licence fee income;
- (b) Bulk products — manufacture and sale of vitamin C and antibiotic products in bulk powder form; and
- (c) Functional food and others — manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare services and others.

SALE OF GOODS

Revenue is recognised at a point in time when control of the goods has been transferred, being when the goods have been delivered to the customer's specific location. Following the delivery, the customer bears the risks of obsolescence and loss in relation to the goods.

LICENCE FEE INCOME

(i) Revenue recognised at a point in time

The Group provides licence of its patented intellectual property or commercialisation rights to customers. Licence fee income is recognised at a point in time when the customer obtains control of the intellectual property. The consideration received comprises a fixed element (the upfront payment) and variable elements (including but not limited to milestone payments and sales-based royalties).

For licence associated with customers' right to use, upfront payment received is initially recorded as contract liabilities and recognised as revenue only when customers have ability to use the licence and variable consideration is recognised only to the extent that it is highly probable that such an inclusion will not result in a significant revenue reversal in the future.

In January 2026, the Group entered into a strategic collaboration and licence agreement with a customer, pursuant to which the Group granted an exclusive licence and agreed to perform certain research and development activities. The Group received US\$1,200,000,000 (equivalent to RMB8,200,104,000) from the customer on 29 May 2026.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

3. REVENUE AND SEGMENT INFORMATION (continued)

LICENCE FEE INCOME (continued)

(i) Revenue recognised at a point in time (continued)

During the six months ended 30 June 2026, revenue of US\$840,000,000 (equivalent to RMB5,740,073,000) was recognised at a point in time when control of the licence is transferred to the customer and the customer is able to use and benefit from the licence. As at 30 June 2026, the remaining upfront payment of US\$360,000,000 (equivalent to RMB2,460,031,000) is refundable subject to certain contractual conditions and included in the other payables under current liabilities.

(ii) Revenue recognised over time

The Group enters into collaboration agreements to grant licences to customers and perform research and development activities. Revenue is recognised over time on a systematic basis that reflects the customer's receipt and consumption of the benefits, by reference to the progress towards complete satisfaction of the relevant performance obligation.

SEGMENT REVENUES AND RESULTS

The following is an analysis of the Group's revenue and results by operating and reportable segments.

For the six months ended 30 June 2026

	Finished drugs RMB'000	Bulk products Vitamin C RMB'000	Antibiotics RMB'000	Functional food and others RMB'000	Segment total RMB'000	Eliminations RMB'000	Consolidated RMB'000
Segment revenue							
Sale of goods	10,165,743	1,010,152	650,233	873,397	12,699,525	-	12,699,525
Inter-segment sales	-	2,754	82,334	57,572	142,660	(142,660)	-
Licence fee income	5,894,969	-	-	-	5,894,969	-	5,894,969
Total revenue	16,060,712	1,012,906	732,567	930,969	18,737,154	(142,660)	18,594,494
Segment profit	7,277,552	40,849	61,533	99,439			7,479,373
Unallocated income							138,773
Unallocated expenses							(71,781)
Share of results of associates							(10,630)
Share of results of joint ventures							6,706
Finance costs							(13,318)
Profit before tax							7,529,123

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

3. REVENUE AND SEGMENT INFORMATION (continued)

SEGMENT REVENUES AND RESULTS (continued)

For the six months ended 30 June 2025

	Finished drugs RMB'000	Bulk products		Functional food and others RMB'000	Segment total RMB'000	Eliminations RMB'000	Consolidated RMB'000
		Vitamin C RMB'000	Antibiotics RMB'000				
Segment revenue							
Sale of goods	9,172,985	1,196,107	878,601	951,056	12,198,749	–	12,198,749
Inter-segment sales	–	2,106	68,063	12,873	83,042	(83,042)	–
Licence fee income	1,074,667	–	–	–	1,074,667	–	1,074,667
Total revenue	10,247,652	1,198,213	946,664	963,929	13,356,458	(83,042)	13,273,416
Segment profit	2,392,744	180,983	145,224	209,421			2,928,372
Unallocated income							276,533
Unallocated expenses							(52,817)
Share of results of associates							(14,709)
Share of results of joint ventures							1,940
Finance costs							(21,652)
Profit before tax							3,117,667

Segment profit represents the profit earned by each segment without allocation of interest income, fair value changes on structured bank deposits, fair value changes on financial assets measured at FVTPL, central administrative expenses, share of results of associates and joint ventures and finance costs. This is the measure reported to the executive directors for the purposes of resources allocation and performance assessment.

Inter-segment sales are charged at prevailing market rates.

The executive directors make decisions according to operating results of each segment. No analysis of segment asset and segment liability is presented as the executive directors do not regularly review such information for the purposes of resources allocation and performance assessment. Therefore, only segment revenue and segment results are presented.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

3. REVENUE AND SEGMENT INFORMATION *(continued)*

GEOGRAPHICAL INFORMATION

Revenue from the external customers by geographical market (irrespective of the origin of the goods or licence) based on the location of the customers are presented below:

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Chinese mainland	10,904,595	10,553,392
Other Asian regions	644,233	662,101
Europe	6,224,852	1,215,560
North America	537,481	499,403
Others	283,333	342,960
	18,594,494	13,273,416

4. PROFIT BEFORE TAX

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Profit before tax has been arrived at after charging/(crediting):		
Depreciation of property, plant and equipment	502,822	520,144
Depreciation of right-of-use assets	78,365	91,761
Depreciation of investment properties	2,098	1,653
Amortisation of intangible assets	79,392	77,937
Total depreciation and amortisation	662,677	691,495
Recognition of (reversal of) employee share-based compensation expenses	115,323	(72,010)
Government grant income (included in other income)	(87,857)	(142,906)
Fair value gain on financial assets measured at FVTPL (included in other gains or losses)	(34,418)	(164,591)
Fair value gain on structured bank deposits (included in other gains or losses)	(18,189)	(16,969)
Fair value gain on derivative financial instruments (included in other gains or losses)	(7,990)	–
Impairment losses recognised under expected credit loss model (included in other gains or losses)	6,192	7,713
Interest income on bank deposits and balances (included in other income)	(91,678)	(94,749)
Loss on disposal of property, plant and equipment (included in other gains or losses)	6,794	666
Net foreign exchange loss/(gain) (included in other gains or losses)	137,420	(17,342)

For the six months ended 30 June 2026 and 2025, cost of inventories recognised as an expense approximated cost of sales as shown in the condensed consolidated income statement.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

5. INCOME TAX EXPENSE

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Current taxation		
— PRC Enterprise Income Tax	848,094	397,684
— PRC withholding tax on dividends distributed by subsidiaries	152,382	69,515
— Overseas taxation	24,755	6,232
	1,025,231	473,431
Deferred taxation	43,716	70,186
	1,068,947	543,617

No provision for Hong Kong Profits Tax has been made as the Group did not have assessable profits for both periods.

The standard tax rate of the Company's PRC subsidiaries is 25% under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and implementation regulations of the EIT Law. Certain subsidiaries of the Company are qualified as High and New Technology Enterprises, and they are subject to a preferential tax rate of 15%.

Under the EIT Law, dividends distributed by a company established in the PRC to foreign investor with respect to profits earned from 1 January 2008 onwards are subject to a withholding tax of 10%. The tax rate was reduced to 5% as the Company and certain subsidiaries acting as foreign investors, met the required conditions specified in the relevant tax regulations.

Taxation arising in other jurisdictions is calculated at the rates prevailing in relevant jurisdictions.

The Group is operating in certain jurisdictions where the Pillar Two Rules are effective. As the Group's estimated effective tax rates of such in-effect jurisdiction in which the Group operates is higher than 15%, after taking into account the adjustments under the Global Anti-base Erosion Rules based on management's best estimate, the management of the Group considered the Group is not liable to top-up tax under the Pillar Two Rules.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

6. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share is as follows:

	Six months ended 30 June	
	2026	2025
Profit attributable to owners of the Company (RMB'000)	6,094,212	2,547,851
Weighted average number of ordinary shares for the purpose of basic earnings per share (in '000)	11,401,166	11,432,814
Effect of dilutive potential ordinary shares:		
Share options and share awards (in '000)	18,737	113
Weighted average number of ordinary shares for the purpose of diluted earnings per share (in '000)	11,419,903	11,432,927

The weighted average number of ordinary shares for the calculation of basic earnings per share for both periods have been adjusted for the shares held by the trustee pursuant to the share award scheme of the Company.

7. DIVIDENDS

(a) INTERIM DIVIDEND

The Board of Directors has declared the payment of an interim dividend of HK18 cents per share for 2026 (2025: HK14 cents (approximately RMB12.8 cents) per share amounting to approximately RMB1,470,541,000) subsequent to the end of the reporting period, which has not been recognised as a liability at the end of the reporting period.

(b) FINAL DIVIDEND APPROVED DURING THE CURRENT INTERIM PERIOD

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Final dividend in respect of the previous financial year, approved during the following interim period, of HK15 cents (approximately to RMB13.0 cents) (2025: HK10 cents (approximately to RMB9.1 cents)) per share	1,501,260	1,050,465
Less: Dividend for shares held by share award scheme	(21,260)	(9,120)
	1,480,000	1,041,345

A final dividend of HK15 cents per share in respect of the year ended 31 December 2025 (six months ended 30 June 2025: HK10 cents per share in respect of the year ended 31 December 2024) was declared during the current interim period. The dividend was recognised as a liability at the end of the reporting period and paid to the owners of the Company subsequent to the end of the reporting period.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

8. PROPERTY, PLANT AND EQUIPMENT

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Cost		
At beginning of the period	19,422,377	17,742,574
Additions	628,257	925,320
Acquisition of subsidiaries	121,792	–
Disposals	(99,110)	(97,981)
Dissolution of a subsidiary	(4,422)	–
Exchange adjustments	(2,201)	(1,706)
At end of the period	20,066,693	18,568,207
Accumulated depreciation		
At beginning of the period	(7,269,215)	(6,368,132)
Provided during the period	(502,822)	(520,144)
Eliminated on disposals	40,044	92,012
Eliminated on dissolution of a subsidiary	3,114	–
Exchange adjustments	433	(224)
At end of the period	(7,728,446)	(6,796,488)
Net carrying amount		
At end of the period	12,338,247	11,771,719
At beginning of the period	12,153,162	11,374,442

9. RIGHT-OF-USE ASSETS

	Six months ended 30 June	
	2026 RMB'000	2025 RMB'000
Net carrying amount at beginning of the period	1,336,253	1,128,458
Additions	43,750	206,006
Depreciation provided during the period	(78,365)	(91,761)
Exchange adjustments	(1,570)	(279)
Net carrying amount at end of the period	1,300,068	1,242,424

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

10. INTANGIBLE ASSETS

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Cost		
At beginning of the period	3,625,303	3,305,776
Additions	289,924	123,810
Exchange adjustments	(987)	(135)
At end of the period	3,914,240	3,429,451
Accumulated amortisation and impairment loss		
At beginning of the period	(850,432)	(696,270)
Provided during the period	(79,392)	(77,937)
Exchange adjustments	856	108
At end of the period	(928,968)	(774,099)
Net carrying amount		
At end of the period	2,985,272	2,655,352
At beginning of the period	2,774,871	2,609,506

11. OTHER FINANCIAL ASSETS

	30 June 2026	31 December 2025
	RMB'000	RMB'000
Unlisted investments in partnerships and funds	1,455,549	1,566,220
Listed equity securities	267,417	269,975
Unlisted equity securities	415,640	415,081
Investment in convertible bonds	59,065	—
	2,197,671	2,251,276
Financial assets measured at FVTPL	1,639,975	1,680,295
Financial assets measured at FVTOCI (note)	557,696	570,981
	2,197,671	2,251,276
Analysed as:		
Current	59,065	—
Non-current	2,138,606	2,251,276
	2,197,671	2,251,276

Note: The above investments are mainly focused on the healthcare industry. The directors of the Company have elected to designate these investments to be measured at FVTOCI as they believe that recognising short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for long-term purposes and realising their performance potential in the long run.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

11. OTHER FINANCIAL ASSETS (continued)

The directors of the Company consider that the Group does not have any control nor significant influence to affect the variable returns through its investment in those enterprises or similar activities.

During the current interim period, the Group received RMB138,765,000 (six months ended 30 June 2025: RMB58,089,000) upon distribution by the partnerships and funds, which was also the fair value as at the date of distribution.

12. TRADE RECEIVABLES

	30 June 2026 RMB'000	31 December 2025 RMB'000
Trade receivables	5,444,033	4,827,337
Less: allowance for expected credit loss	(54,662)	(48,470)
	5,389,371	4,778,867

The Group allows a general credit period of 90 days to its trade customers. The following is an aged analysis of trade receivables (net of allowance for expected credit loss) at the end of the reporting period presented based on invoice dates which approximated the respective revenue recognition dates:

	30 June 2026 RMB'000	31 December 2025 RMB'000
0 to 90 days	4,775,753	4,228,179
91 to 180 days	582,548	484,326
181 to 365 days	28,893	59,095
More than 365 days	2,177	7,267
	5,389,371	4,778,867

13. DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

	30 June 2026 RMB'000	31 December 2025 RMB'000
Prepayments for raw materials and research and development expenses	247,540	211,899
Deposits paid for acquisition of property, plant and equipment and right-of-use assets	566,511	556,488
Other taxes recoverable	711,625	761,464
Utility deposits	164,104	133,949
Others	453,838	400,082
	2,143,618	2,063,882
Analysed as:		
Current	1,577,107	1,507,394
Non-current	566,511	556,488
	2,143,618	2,063,882

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

14. BILLS RECEIVABLES

The bills receivables of the Group are with a maturity period of less than 365 days (31 December 2025: less than 365 days) and not yet due at the end of the reporting period. The management considers the default rate is low based on historical information, experience and forward-looking information that is available without undue cost or effort.

15. STRUCTURED BANK DEPOSITS

The structured bank deposits carry guaranteed return of up to 1.20% (31 December 2025: 2.55%) per annum and have a total expected return up to 2.10% (31 December 2025: 4.55%) per annum, depending on the market prices of the underlying commodities quoted in the market as specified in the terms of relevant deposits.

The structured bank deposits are designated at FVTPL on initial recognition as they contain non-closely related embedded derivatives.

16. BANK DEPOSITS, BALANCES AND CASH

	30 June 2026 RMB'000	31 December 2025 RMB'000
Time deposits with maturities over 3 months	4,386,142	4,208,538
Pledged and restricted bank deposits	124,748	18,220
Bank balances and cash	9,666,241	5,254,498
	14,177,131	9,481,256
Analysed as:		
Current	10,001,506	6,089,565
Non-current	4,175,625	3,391,691
	14,177,131	9,481,256

The bank deposits and balances carry interest at market rates ranging from 0.05% to 2.60% (31 December 2025: 0.60% to 4.55%) per annum.

The pledged and restricted bank deposits represent deposits required to be placed in banks for securing short-term bank facilities of the Group and are classified as current assets.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

17. TRADE PAYABLES

The following is an aged analysis of trade payables at the end of the reporting period presented based on the invoice dates:

	30 June 2026 RMB'000	31 December 2025 RMB'000
0 to 90 days	1,886,606	1,988,116
91 to 180 days	247,776	154,663
More than 180 days	214,374	179,225
	2,348,756	2,322,004

The general credit period on purchases of goods is up to 90 days (31 December 2025: 90 days).

18. OTHER PAYABLES

	30 June 2026 RMB'000	31 December 2025 RMB'000
Other tax payable	463,815	340,226
Payables arising from construction cost and acquisition of property, plant and equipment	888,228	1,015,294
Deferred government grants	774,688	797,190
Dividend payable (note 7)	1,480,000	–
Salaries, wages and staff welfare payable	347,587	520,627
Selling expense payable	2,667,194	2,455,746
Research and development expense payable	759,548	296,742
Refundable upfront payment received (Note)	2,460,031	–
Others	616,118	471,527
	10,457,209	5,897,352
Analysed as:		
Current	9,916,566	5,334,111
Non-current	540,643	563,241
	10,457,209	5,897,352

Note: Refundable upfront payment received represents the upfront payment received from a customer under a strategic collaboration and licence agreement in relation to the grant of licence and the performance of research and development activities. The amount is refundable subject to certain contractual conditions. Based on the facts and circumstances existing as at 30 June 2026, including the current status of the collaboration and the Group's ongoing performance of the relevant research and development activities, management does not expect that the amount will be refunded.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

19. BILLS PAYABLES

All bills payables of the Group are aged within 365 days (31 December 2025: within 365 days) and not yet due at the end of the reporting period.

20. BANK BORROWINGS

	30 June 2026 RMB'000	31 December 2025 RMB'000
Discount of bills receivables (note a)	128,875	307,723
RMB bank loans (note b)	274,406	21,000
	403,281	328,723

Notes:

- The amount represents borrowings secured by the bill receivables discounted to banks with recourse and the amount is repayable within one year and classified as current liability.
- As at 30 June 2026, the bank loans carry variable interest rates based on the Loan Prime Rate (LPR) and the amounts are repayable after one year and classified as non-current liabilities. As at 31 December 2025, the bank loan carried a fixed interest rate of 1.95% per annum and was repaid during the six months ended 30 June 2026.

21. CONTRACT LIABILITIES

	30 June 2026 RMB'000	31 December 2025 RMB'000
Advances from customers	212,064	233,743
Upfront fee received in advance	1,279,640	1,279,640
	1,491,704	1,513,383
Analysed as:		
Current	640,568	662,247
Non-current	851,136	851,136
	1,491,704	1,513,383

Contract liabilities represent consideration received by the Group from customers in advance of the satisfaction of the relevant performance obligations, including advances received from customers for the delivery of products and upfront payments received for licences associated with customers' right to use.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

22. SHARE CAPITAL

	Number of shares	Share capital RMB'000
Issued and fully paid		
At 1 January 2025	11,638,301,732	11,032,752
Repurchased and cancelled during the period	(120,050,000)	–
Exercise of share options	500,000	3,417
At 30 June 2025	11,518,751,732	11,036,169
Exercise of share options	3,700,000	25,260
At 31 December 2025 and 30 June 2026	11,522,451,732	11,061,429

In January 2025, the Company cancelled 55,750,000 of its own ordinary shares that had not been cancelled as at 31 December 2024. During the six months ended 30 June 2025, the Company further repurchased and cancelled an aggregate of 64,300,000 of its own ordinary shares through the Stock Exchange, for a total consideration (before expenses) of RMB277,634,000 (equivalent to HK\$299,515,000).

23. LONG TERM INCENTIVE PROGRAM

(i) SHARE OPTION SCHEME

2015 Share Option Scheme

The share option scheme of the Company adopted on 9 December 2015 (the “2015 Share Option Scheme”) is for the purpose of providing the Company with a flexible means of giving incentive to eligible participants. Participants include any director, employee, business consultant, professional and other adviser of the Group. The 2015 Share Option Scheme expired on 8 December 2025.

The maximum number of shares which may be issued upon exercise of all share options to be granted under the 2015 Share Option Scheme shall not in aggregate exceed 591,101,840 shares, being 10% of the shares of the Company in issue at adoption the date of the 2015 Share Option Scheme. The maximum entitlement for any one participant is that the total number of shares issued or to be issued upon exercise of the share options granted to each participant in any twelve-month period shall not exceed 1% of the total number of shares in issue.

Share options granted have to be taken up within an acceptable period from the date of offer to such date as the Board may determine and specify in the letter of offer (both dates inclusive) upon payment of HK\$1. The subscription price for option granted is determined by the Board and shall be at least the highest of (i) the closing price of the shares as stated in the Stock Exchange's daily quotation sheet on the offer date which must be a business day; (ii) the average closing price of the shares as stated in the Stock Exchange's daily quotation sheets for the five business days immediately preceding the offer date; and (iii) the nominal value of a share. Share options granted are exercisable for a period to be notified by the Board to each grantee and such period shall expire not later than 10 years from the date of grant.

23. LONG TERM INCENTIVE PROGRAM *(continued)*

(i) SHARE OPTION SCHEME *(continued)*

2015 Share Option Scheme *(continued)*

During the six months ended 30 June 2026 and 2025, no share option was granted under the 2015 Share Option Scheme. As at 1 January 2025 and 30 June 2025, the number of share options available for being further granted was 541,101,840. The 2015 Share Option Scheme expired on 8 December 2025 and no more share options may be granted under the 2015 Share Option Scheme since then.

2026 Share Option Scheme

The share option scheme of the Company adopted on 28 May 2026 (the “2026 Share Option Scheme”) is for the purpose of providing the Company with a flexible means of rewarding, remunerating, compensating and/or providing benefits to eligible participants. Participants include directors (including executive, non-executive or independent non-executive directors), the chief executive, and employees of the Group. The 2026 Share Option Scheme is valid and effective for a period of 10 years commencing on the adoption date and will expire on 27 May 2036.

The maximum number of shares which may be issued upon exercise of all share options to be granted under the 2026 Share Option Scheme shall not in aggregate exceed 1,152,245,173 shares, being 10% of the shares of the Company in issue at the adoption date of the 2026 Share Option Scheme. The maximum entitlement for any one participant is that the total number of shares issued or to be issued upon exercise of the share options granted to each participant in any twelve-month period shall not exceed 1% of the total number of shares in issue.

Share options granted have to be taken up within an acceptable period from the date of offer to such date as the Board may determine and specify in the letter of offer (both dates inclusive) upon payment of HK\$1. The subscription price for options granted is determined by the Board and shall be at least the higher of (i) the closing price of the shares as stated in the Stock Exchange’s daily quotations sheet on the offer date which must be a business day; and (ii) the average closing price of the shares as stated in the Stock Exchange’s daily quotations sheets for the five business days immediately preceding the offer date. Share options granted are exercisable for a period to be notified by the Board to each grantee and such period shall expire not later than 10 years from the date of grant.

During the six months ended 30 June 2026, no share option was granted under the 2026 Share Option Scheme. As at 30 June 2026, the number of share options available for being further granted under the 2026 Share Option Scheme was 1,152,245,173 (1 January 2026: Nil).

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

23. LONG TERM INCENTIVE PROGRAM (continued)

(i) SHARE OPTION SCHEME (continued)

Six months ended 30 June 2026

The following tables disclose the movements in the number of share options during the current and prior interim periods:

Grantees	Date of grant	Exercise price	Exercise period	Number of share options				As at 30 June 2026
				As at 1 January 2026	Granted during the period	Exercised during the period	Lapsed during the period	
Employees (former directors)	4 September 2023	HK\$5.98	4 September 2023 to 3 September 2033	1,300,000	-	-	-	1,300,000

Six months ended 30 June 2025

Grantees	Date of grant	Exercise price	Exercise period	Number of share options				As at 30 June 2025
				As at 1 January 2025	Granted during the period	Exercised during the period	Lapsed during the period	
Directors	4 September 2023	HK\$5.98	4 September 2023 to 3 September 2033	22,000,000	-	-	(20,500,000)	1,500,000
Employees (former directors)	4 September 2023	HK\$5.98	4 September 2023 to 3 September 2033	8,500,000	-	(500,000)	(4,500,000)	3,500,000
Total				30,500,000	-	(500,000)	(25,000,000)	5,000,000

Notes:

- 50% of the share options granted on 4 September 2023 have been vested on 1 April 2024. The remaining 50% were lapsed on 1 April 2025 as certain vesting conditions were not fulfilled.
- In respect of the share options exercised during the six months ended 30 June 2025, the weighted average closing price of the Company's share immediately before the date on which the options were exercised was HK\$8.84.
- The share options outstanding as at 30 June 2026 has a weighted average remaining contractual life of 7.5 years (31 December 2025: 8 years).

No share-based compensation expense was recognised by the Group during the six months ended 30 June 2026 (six months ended 30 June 2025: nil) in relation to share options granted by the Company.

23. LONG TERM INCENTIVE PROGRAM *(continued)*

(ii) SHARE AWARD SCHEME

2018 Share Award Scheme

The share award scheme of the Company adopted on 20 August 2018 (the “2018 Share Award Scheme”) is for the purpose of providing the selected participants with an opportunity to acquire a proprietary interest in the Company; encouraging and retaining such individuals to work with the Company; and providing additional incentives to them to achieve performance goals, with a view to achieving the objectives of increasing the value of the Company and aligning the interests of the selected participants directly to the shareholders through ownership of shares of the Company. Participants include any director, employee, officer, agent or consultant of the Group. The 2018 Share Award Scheme will expire on 19 August 2028.

The terms of the 2018 Share Award Scheme were amended on 21 May 2024 to the effect that the Board may only instruct the trustee to purchase existing shares of the Company on market to satisfy share awards granted under the 2018 Share Award Scheme, such that the 2018 Share Award Scheme has become a share scheme that is funded only by the existing shares of the Company.

The maximum number of shares which may be purchased from the market or issued under the 2018 Share Award Scheme shall not in aggregate exceed 124,860,368 shares, being 2% of the shares of the Company in issue as at the adoption date of the 2018 Share Award Scheme. The maximum number of shares which may be awarded to a selected participant at any one time or in aggregate under the 2018 Share Award Scheme must not exceed 31,215,092 shares, being 0.5% of the shares of the Company in issue as at the adoption date of the 2018 Share Award Scheme.

The awarded shares held by the trustee of the 2018 Share Award Scheme shall be vested in the selected participants in accordance with the vesting conditions or vesting schedules as set out in the grant notice. Awarded shares which do not vest will be forfeited and may be re-granted to other participants selected by the Board.

As at 30 June 2026, the number of share awards available for being further granted under the 2018 Share Award Scheme was 60,207,868 (1 January 2026: 108,038,368). There were 117,000,000 shares of the Company held by the trustee of the 2018 Share Award Scheme (31 December 2025: 117,000,000).

23. LONG TERM INCENTIVE PROGRAM *(continued)*

(ii) SHARE AWARD SCHEME *(continued)*

2026 Share Award Scheme

The share award scheme of the Company adopted on 25 March 2026 (the “2026 Share Award Scheme”) is for the purpose of providing the selected participants with an opportunity to acquire a proprietary interest in the Company; encouraging and retaining such individuals to work with the Company; and providing additional incentives to them to achieve performance goals, with a view to achieving the objectives of increasing the value of the Company and aligning the interests of the selected participants directly to the shareholders through ownership of shares of the Company. Participants include any director (including executive and non-executive director), employee or officer of the Group. The 2026 Share Award Scheme will expire on 24 March 2036.

The 2026 Share Award Scheme does not involve granting awards that are to be satisfied by the issue of new shares. The Board may only instruct the trustee to purchase existing shares of the Company on the market to satisfy share awards granted under the 2026 Share Award Scheme, such that it is a share scheme funded only by the existing shares of the Company.

The maximum number of shares which may be purchased from the market under the 2026 Share Award Scheme shall not in aggregate exceed 345,673,551 shares, being 3% of the shares of the Company in issue as at the adoption date of the 2026 Share Award Scheme. The maximum number of shares which may be awarded to a selected participant at any one time or in aggregate under the 2026 Share Award Scheme must not exceed 57,612,258 shares, being 0.5% of the shares of the Company in issue as at the adoption date of the 2026 Share Award Scheme.

The awarded shares held by the trustee of the 2026 Share Award Scheme shall be vested in the selected participants in accordance with the vesting conditions or vesting schedules as set out in the grant notice. Awarded shares which do not vest will be forfeited and may be re-granted to other participants selected by the Board.

During the six months ended 30 June 2026, the trustee of the 2026 Share Award Scheme purchased a total of 46,178,000 shares of the Company on the Stock Exchange to be held on trust for a total consideration of approximately HK\$321,086,000 (equivalent to approximately RMB279,699,000), pursuant to the terms and conditions of the 2026 Share Award Scheme.

As at 30 June 2026, the number of share awards available for being further granted under the 2026 Share Award Scheme was 345,673,551 (1 January 2026: Nil). There were 46,178,000 shares of the Company held by the trustee of the 2026 Share Award Scheme (31 December 2025: Nil).

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

23. LONG TERM INCENTIVE PROGRAM (continued)

(ii) SHARE AWARD SCHEME (continued)

The following tables disclose the movements in the number of awarded shares during the current and prior interim periods:

Six months ended 30 June 2026

Grantees	Date of grant	Vesting period	Number of awarded shares				As at 30 June 2026
			As at 1 January 2026	Granted during the period	Vested during the period	Cancelled/ lapsed during the period	
Employees	22 April 2024	22 April 2024 to 21 April 2027	300,000	-	-	-	300,000
	19 September 2025	19 September 2025 to 30 January 2029	9,000,000	-	-	(9,000,000)	-
	23 January 2026	23 January 2026 to 23 January 2029	-	46,462,500	-	(444,000)	46,018,500
	2 April 2026	2 April 2026 to 23 January 2029	-	9,462,000	-	-	9,462,000
	8 June 2026	8 June 2026 to 23 January 2028	-	1,350,000	-	-	1,350,000
Total			9,300,000	57,274,500	-	(9,444,000)	57,130,500

Six months ended 30 June 2025

Grantees	Date of grant	Vesting period	Number of awarded shares				As at 30 June 2025
			As at 1 January 2025	Granted during the period	Vested during the period	Cancelled/ lapsed during the period	
Employees	22 April 2024	22 April 2024 to 21 April 2027	300,000	-	-	-	300,000
Total			300,000	-	-	-	300,000

During the current interim period, the Group recognised share-based compensation expense of RMB86,852,000 (six months ended 30 June 2025: RMB270,000) in relation to share awards granted by the Company.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

23. LONG TERM INCENTIVE PROGRAM *(continued)*

(iii) SHARE AWARDS GRANTED BY A SHAREHOLDER

Key Honesty Limited ("Key Honesty"), a shareholder of the Company indirectly and wholly owned by Mr. Cai Dong Chen, Chairman of the Company, has granted 218,250,000 and 8,900,000 share awards involving the existing shares of the Company held by Key Honesty to selected employees of the Group on 1 April 2022 and 14 September 2022, respectively. The awarded shares will be vested and transferred in batches from the third to fifth year after the grant at a transfer price of HK\$2.95 per share subject to the fulfilment of certain conditions.

The following tables disclose the movements in the number of awarded shares during the current and prior interim periods:

Six months ended 30 June 2026

Grantees	Date of grant	Vesting period	Number of awarded shares				As at 30 June 2026
			As at 1 January 2026	Granted during the period	Vested during the period	Cancelled/ lapsed during the period	
Employees	1 April 2022	1 April 2022 to 31 December 2026	37,845,000	-	-	(5,100,000)	32,745,000
	1 April 2022	1 April 2022 to 1 April 2027	50,460,000	-	-	(6,800,000)	43,660,000
	14 September 2022	14 September 2022 to 31 December 2026	450,000	-	-	-	450,000
	14 September 2022	14 September 2022 to 14 September 2027	600,000	-	-	-	600,000
Total			89,355,000	-	-	(11,900,000)	77,455,000

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

23. LONG TERM INCENTIVE PROGRAM *(continued)*

(iii) SHARE AWARDS GRANTED BY A SHAREHOLDER *(continued)*

Six months ended 30 June 2025

Grantees	Date of grant	Vesting period	Number of awarded shares				As at 30 June 2025
			As at 1 January 2025	Granted during the period	Vested during the period	Cancelled/ lapsed during the period	
Employees	1 April 2022	1 April 2022 to 1 April 2025	54,045,000	–	(37,845,000)	(16,200,000)	–
	1 April 2022	1 April 2022 to 1 April 2026	54,045,000	–	–	(16,200,000)	37,845,000
	1 April 2022	1 April 2022 to 1 April 2027	72,060,000	–	–	(21,600,000)	50,460,000
	14 September 2022	14 September 2022 to 14 September 2025	780,000	–	–	(210,000)	570,000
	14 September 2022	14 September 2022 to 14 September 2026	780,000	–	–	(210,000)	570,000
	14 September 2022	14 September 2022 to 14 September 2027	1,040,000	–	–	(280,000)	760,000
Total			182,750,000	–	(37,845,000)	(54,700,000)	90,205,000

During the current interim period, the Group recognised share-based compensation expense of RMB28,471,000 (six months ended 30 June 2025: a reversal of share-based compensation expense of RMB72,280,000) in relation to the share awards granted by Key Honesty.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

24. RELATED PARTY DISCLOSURES

During the current interim period, the Group had significant transactions and balances with related parties. Other than those disclosed elsewhere in the condensed consolidated financial statements, the Group had also entered into the following significant transactions with related parties and the balances with them at the end of the reporting period are as follows:

Relationships	Nature of transactions/balances	Six months ended 30 June	
		2026 RMB'000	2025 RMB'000
Related companies (note a)	Sales of pharmaceutical products	562,755	432,711
	Purchase of pharmaceutical products and raw materials	213,343	124,312
	Payment of lease liabilities	63,579	65,319
	Consolidated service expense	59,504	54,410
		30 June 2026 RMB'000	31 December 2025 RMB'000
	Balance due from/to the related companies		
	— trade receivables (note b)		
	aged 0–90 days	325,057	320,786
	aged 91–180 days	914	2,011
	aged 181–365 days	469	606
	aged over 365 days	2,675	2,675
		329,115	326,078
	— other receivables (note c)	5,691	17,608
	— trade payables (note b)		
	aged 0–90 days	(98,547)	(128,142)
	aged 91–180 days	(21,668)	(23,655)
	aged 181–365 days	(470)	(85,226)
	aged over 365 days	(69,653)	(40,819)
		(190,338)	(277,842)
	— other payables (note c)	(19,873)	(27,703)
	— lease liabilities	(202,238)	(257,490)

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

24. RELATED PARTY DISCLOSURES (continued)

Relationships	Nature of transactions/balances	Six months ended 30 June	
		2026 RMB'000	2025 RMB'000
Joint ventures	Sales of pharmaceutical products	28,975	76,401
	Purchase of raw materials	68,489	150,770
	Research and development expenses	–	9,557
		30 June 2026 RMB'000	31 December 2025 RMB'000
	Balance due from/(to) joint ventures		
	– trade receivables (note b)		
	aged 0–90 days	8,513	7,833
	aged 91–180 days	–	694
		8,513	8,527
	– other receivables (note c)	43,751	74,941
	– trade payables (note b)		
	aged 0–90 days	(86,186)	(53,323)
	aged 91–180 days	(15,460)	(23,362)
	aged 181–365 days	(2,588)	(47,217)
	aged over 365 days	–	(31,591)
		(104,234)	(155,493)
	– other payables (note c)	(47,577)	(55,295)

Notes:

- (a) Mr. Cai Dong Chen, executive director and the Chairman of the Company, has significant influence over the Company and exercises control over CHL through a series of controlled corporations. Accordingly, CHL and its subsidiaries are related parties of the Group.
- (b) The general credit period for trade receivables and payables is 90 days (31 December 2025: 90 days).
- (c) The amounts are unsecured, non-interest bearing and repayable on demand.

On 25 February 2026, CSPC Innovation Pharmaceutical Co., Ltd. (a non-wholly owned subsidiary of the Company) entered into an equity transfer agreement with CHL to dispose of its 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd. for a consideration of RMB230,000,000. The disposal was approved by the shareholders of CSPC Innovation Pharmaceutical Co., Ltd. on 8 April 2026 and was subsequently completed during the period, resulting in a gain on disposal of RMB896,000.

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

25. CAPITAL COMMITMENTS

At the end of the reporting period, the Group had the following capital commitments:

	30 June 2026 RMB'000	31 December 2025 RMB'000
Capital expenditure in respect of acquisition of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements	1,547,643	1,765,397
Commitments arising from unlisted equity investments in partnerships	559,792	565,099

26. FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

Certain financial assets of the Group are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation technique(s) and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categorised (Levels 1 to 3) based on the degree to which the inputs to the fair value measurements are observable.

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active market for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include the lowest level inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2026 (Unaudited)

26. FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (continued)

Financial assets	Fair value as at		Fair value hierarchy	Valuation techniques and key input(s)	Significant unobservable input(s)	Relationship of unobservable inputs to fair value
	30 June 2026 RMB'000	31 December 2025 RMB'000				
Equity securities listed in Hong Kong	267,417	269,975	Level 1	Quoted bid prices in an active market.	N/A	N/A
Unquoted investments	1,930,254	1,981,301	Level 3	Where recent transaction prices of underlying investments is not available, discounted cash flows is used for valuation.	Estimated discount rate	The higher the estimated discount rate, the lower the fair value, vice versa.
				Discounted cash flows — in this approach, the discounted cash flow method was used to capture the present value of future expected cash flows to be derived from the underlying assets.	Long-term pre-tax operating margin	The higher the long-term pre-tax operating margin, the higher the fair value, vice versa.
Derivative financial assets -foreign currency swaps	7,990	—	Level 2	Discounted cash flows — Future cash flows are estimated based on the difference between the contracted forward exchange rates and observable market forward exchange rates at the end of the reporting period, discounted at a rate that reflects the credit risk of the counterparties.	N/A	N/A
Bills receivables measured at FVTOCI	1,588,055	2,506,687	Level 2	Discounted cash flow at a discount rate that reflects the credit risk of issuers.	N/A	N/A
Structured bank deposits	8,485,866	2,775,915	Level 2	Expected yields of underlying investments invested by bank at a discount rate that reflects the credit risk of the bank.	N/A	N/A

There were no transfers between levels during the current interim period.

Unrealised fair value loss of RMB14,130,000 included in other comprehensive expense for the period ended 30 June 2026 (six months ended 30 June 2025: unrealised fair value loss of RMB120,631,000) was related to other financial assets measured at FVTOCI held at the end of the reporting period and reported as changes in other reserves.

26. FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(continued)*

FAIR VALUE MEASUREMENTS AND VALUATION PROCESSES

In estimating the fair value of an asset or a liability, the Group uses market-observable data to the extent it is available. Where Level 1 and 2 inputs are not available, the Group engages third party qualified valuers to perform the valuation. The finance department works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model. The management reports to the directors of the Company every quarter to explain the cause of fluctuations in the fair value of the assets and liabilities.

Information about the valuation techniques and inputs used in determining the fair value of various assets and liability are disclosed above.

The directors of the Company consider that the carrying amounts of other financial assets and financial liabilities recorded at amortised cost in the condensed consolidated financial statements approximate their fair values.

Other Information

DIRECTORS' INTERESTS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2026, the interests and short positions of the directors of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")), as recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code"), were as follows:

Long Positions

Name of Director	Capacity/ Nature of Interest	Number of shares held	Number of underlying shares held	Total interests in shares/ underlying shares	Approximate % of the issued shares as at 30 June 2026 ⁽¹⁾
The Company					
Cai Dong Chen	Beneficial owner	479,910,960	–	479,910,960	4.17%
	Interest of controlled corporation	2,561,045,710 ⁽²⁾	–	2,561,045,710	22.23%
Cai Lei	Beneficial owner	40,000	–	40,000	0.0003%
Wei Qingjie	Beneficial owner	300,000	–	300,000	0.003%
Zhang Cuilong	Beneficial owner	5,000,000	–	5,000,000	0.04%
Wang Zhenguo	Beneficial owner	1,500,000	–	1,500,000	0.01%
Li Chunlei	Beneficial owner	3,000,000	–	3,000,000	0.03%
Cai Xin	Beneficial owner	100,000	–	100,000	0.001%
Chen Weiping	Beneficial owner	170,000	350,000 ⁽³⁾	520,000	0.005%
Qu Zhiyong	Beneficial owner	90,003	–	90,003	0.001%
CSPC Innovation Pharmaceutical Co., Ltd. (an associated corporation of the Company)					
Qu Zhiyong	Beneficial owner	800	–	800	0.0001%

Notes:

- (1) Based on 11,522,451,732 shares in issue as at 30 June 2026.
- (2) Mr. Cai Dong Chen is deemed to be interested in 2,561,045,710 shares, comprising (i) 367,081,640 shares directly held by Key Honesty Limited ("Key Honesty"), a direct wholly-owned subsidiary of True Ally Holdings Limited ("True Ally"), (ii) 1,218,834,470 shares directly held by Massive Giant Group Limited, a direct wholly-owned subsidiary of True Ally, (iii) 948,249,600 shares directly held by True Ally, which is directly wholly-owned by Mr. Cai Dong Chen and (iv) 26,880,000 shares directly held by Harmonic Choice Limited by virtue of his interests in a chain of corporations holding Harmonic Choice Limited, namely Massive Top Limited, of which March Rise Limited, Beijing Zhongyihe Hezhong Investment Management Centre (Limited Partnership) (北京中宜和合眾投資管理中心(有限合伙)) ("Zhongyihe") and True Ally own 75%, 15% and 10%, respectively. March Rise Limited in turn is owned as to 40% by True Ally and 60% by Zhongyihe, the general partner of which is Mr. Cai Dong Chen.
- (3) The interests represent unvested awarded shares granted by Key Honesty, a shareholder of the Company, details of which are set out in Note 23 to the condensed consolidated financial statements.

Save as disclosed above, none of the Directors or their associates had any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations as at 30 June 2026.

ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES

Other than the long-term incentive programs disclosed below, neither the Company nor any of its subsidiaries was a party to any arrangements to enable the directors of the Company to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate at any time during the six months ended 30 June 2026.

LONG-TERM INCENTIVE PROGRAMS

(1) SHARE OPTION SCHEMES

(i) **2015 Share Option Scheme**

The Company has adopted a share option scheme on 9 December 2015 (the “2015 Share Option Scheme”), details of which are set out in Note 23 to the condensed consolidated financial statements.

On 4 September 2023 (the “Grant Date”), the Company conditionally granted share options (the “Share Options”) to the then directors of the Company set out in the table below (the “Management Grantees”) to subscribe for an aggregate of 50,000,000 shares of the Company (the “Share Option Shares”) under the 2015 Share Option Scheme.

The exercise of the Share Options by the Management Grantees in full (the “Exercise of the Share Options”) would cause the aggregate shareholding interests in the total number of issued shares held by the Management Grantees and parties acting in concert with any of them (collectively, the “Management Group”) to increase from approximately 29.90% of the total number of issued shares of the Company as at the Grant Date to approximately 30.19% of the total number of issued shares of the Company as enlarged by the issuance of the Share Option Shares in full. Accordingly, the Management Grantees would be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code to the shareholders of the Company for all the issued shares not already owned or agreed to be acquired by the Management Group as a result of the allotment and issuance of the Share Option Shares to the Management Grantees, unless a whitewash waiver is granted by the Securities and Futures Commission (“SFC”). The Management Grantees had applied to the SFC for, and the SFC granted, a waiver pursuant to Note 1 of the Notes on dispensations from Rule 26 of the Takeovers Code from the obligations of the Management Grantees to make a mandatory general offer for all of the shares and other securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company (if any) not already owned or agreed to be acquired by the Management Group which would otherwise arise as a result of the completion of the Exercise of the Share Options (the “Whitewash Waiver”).

The resolutions approving the Whitewash Waiver and the conditional grant of the Share Options and the Exercise of the Share Options and the transactions contemplated thereunder were duly passed at the extraordinary general meeting held by the Company on 29 November 2023.

Other Information

On 11 April 2024, a total number of 19,500,000 Share Options were exercised by some of the Management Grantees at the exercise price of HK\$5.98 per share. Accordingly, a total of 19,500,000 new shares were allotted and issued to some of the Management Grantees on 15 April 2024 (the “Issuance”). Pursuant to Note 15 to Rule 25.1 of the Takeovers Code, the Management Group shall be deemed to have a lowest percentage holding equal to its percentage holding immediately after the Issuance, i.e. 30.01% as at 15 April 2024 (the “New Lowest Percentage Holding”). Any acquisition of additional voting rights by the Management Group subsequent to the Issuance shall be subject to the 2% creeper under Rule 26.1 of the Takeovers Code by reference to the New Lowest Percentage Holding in the 12-month period ending on the date of the Issuance, unless any subsequent disposition of voting rights by the Management Group causes the lowest percentage holding of the Management Group to fall below the New Lowest Percentage Holding. Details of the above exercise of Share Options are set out in the announcement of the Company dated 15 April 2024.

The 2015 Share Option Scheme was approved and adopted by the Company’s shareholders on 9 December 2015 and expired on 8 December 2025. No further options can be granted thereunder upon expiration.

Particulars of share options outstanding under the 2015 Share Option Scheme at the beginning and at the end of the six months ended 30 June 2026 and share options granted, exercised, lapsed or cancelled under the 2015 Share Option Scheme during the six-month period were as follows:

						Number of share options					Closing Price of Share	
Name of category of participants	Date of grant	Exercise period	Vesting period	Exercise price at grant date per Share (HK\$)	Unexercised as at 1 January 2026	New grants during the reporting period	Exercised during the reporting period	Lapsed during the reporting period	Cancelled during the reporting period	Unexercised as at 30 June 2026	Prior to the date of grant (HK\$)	Prior to the date of exercise (weighted average) (HK\$)
Other grantees												
in aggregate	4 September 2023	(1)	(2)	5.98	1,300,000	–	–	–	–	1,300,000	5.90	N/A

Notes:

- Subject to the fulfillment of the conditions for the grant and exercise of the share options, the vesting conditions and the vesting period, the exercise period of the share options is 10 years from the date of grant (i.e. 4 September 2023 to 3 September 2033, both days inclusive).
- Conditional upon the Group having achieved a single-digit percentage growth on the amount of the underlying profit attributable to shareholders (i.e. the profit attributable to shareholders after excluding certain non-operating items as determined by the Board) for the year ended 31 December 2023 as compared to that for the year ended 31 December 2022, 50% of the share options shall vest on 1 April 2024, and such condition has already been satisfied. The remaining 50% of the share options shall vest on 1 April 2025 conditional upon the Group having achieved a double-digit percentage growth on the amount of the underlying profit attributable to shareholders (i.e. the profit attributable to shareholders after excluding certain non-operating items as determined by the Board) for the year ended 31 December 2024 as compared to that for the year ended 31 December 2023. Since such condition had not been satisfied, the share options lapsed on 1 April 2025.

(ii) 2026 Share Option Scheme

The Company has adopted a share option scheme on 28 May 2026 (the “2026 Share Option Scheme”), details of which are set out in Note 23 to the condensed consolidated financial statements.

As at the date of adoption of the 2026 Share Option Scheme and 30 June 2026, the total number of shares available for grant under the 2026 Share Option Scheme was 1,152,245,173 shares, representing approximately 10% of the issued shares of the Company.

During the six months ended 30 June 2026, no share options were granted, exercised, lapsed, or cancelled under the 2026 Share Option Scheme, and there were no outstanding share options under the 2026 Share Option Scheme as at 30 June 2026.

(2) SHARE AWARD SCHEMES

(i) 2018 Share Award Scheme

The Company has adopted a share award scheme on 20 August 2018 (the “2018 Share Award Scheme”). In addition, a shareholder of the Company has granted share awards to selected employees of the Group. Details of the 2018 Share Award Scheme are set out in Note 23 to the condensed consolidated financial statements.

Particulars of share award outstanding under the 2018 Share Award Scheme at the beginning and at the end of the six months ended 30 June 2026, together with those granted, vested, lapsed or cancelled under the 2018 Share Award Scheme during the six-month period, were as follows:

Grantees	Date of grant	Vesting period	Number of awarded shares				Closing Price of Shares		
			Unvested	New	Vested	Cancelled/	Unvested	Prior to	Prior to the
			As at 1 January 2026	granted during the reporting period	during the reporting period	lapsed during the reporting period	As at 30 June 2026	the date of grant (HK\$)	vesting (weighted average) (HK\$)
Employees	22 April 2024	22 April 2024 to 21 April 2027	300,000	–	–	–	300,000	5.77	N/A
	19 September 2025	19 September 2025 to 30 January 2029	9,000,000	–	–	(9,000,000)	–	10.14	N/A
	23 January 2026	23 January 2026 to 23 January 2029	–	46,462,500	–	(444,000)	46,018,500	9.68	N/A
	2 April 2026	2 April 2026 to 23 January 2029	–	9,462,000	–	–	9,462,000	9.62	N/A
	8 June 2026	8 June 2026 to 23 January 2028	–	1,350,000	–	–	1,350,000	7.24	N/A
Total			9,300,000	57,274,500	–	(9,444,000)	57,130,500		

As at 1 January 2026 and 30 June 2026, the total number of shares available for further award under the 2018 Share Award Scheme was 108,038,368 shares and 60,207,868 shares respectively, representing approximately 0.94% and 0.52% of the issued shares of the Company.

The 2018 Share Award Scheme was adopted by the Board on 20 August 2018, with subsequent amendments made on 21 May 2024. The 2018 Share Award Scheme shall be valid and effective for a period of ten years from the date of adoption until 19 August 2028, unless terminated earlier by the Board.

As disclosed in the announcement of the Company dated 12 August 2026, the trustee of the 2018 Share Award Scheme was changed from BOCI-Prudential Trustee Limited to BOCI Trustee (Hong Kong) Limited (“BOCI Trustee”) with effect from 12 August 2026. The Company engaged BOCI Trustee as the trustee in replacement of BOCI-Prudential Trustee Limited, and an amended and restated trust deed was executed between the Company and BOCI Trustee to give effect to such change. The change of trustee does not affect the subsisting rights of the selected participants under the 2018 Share Award Scheme.

(ii) 2026 Share Award Scheme

The Company has adopted a share award scheme on 25 March 2026 (the “2026 Share Award Scheme”). Details of the 2026 Share Award Scheme are set out in Note 23 to the condensed consolidated financial statements.

Since the adoption of the 2026 Share Award Scheme and up to 30 June 2026, no share awards were granted, vested, lapsed, or cancelled under the 2026 Share Award Scheme. Accordingly, there were no share awards outstanding as at 30 June 2026.

As at the date of adoption of the 2026 Share Award Scheme and 30 June 2026, the total number of shares available for further award under the 2026 Share Award Scheme was 345,673,551 shares, representing approximately 3.00% of the issued shares of the Company.

The 2026 Share Award Scheme was adopted by the Board on 25 March 2026 and shall be valid and effective for a period of ten years from the date of adoption until 24 March 2036, unless terminated earlier by the Board.

(iii) Share awards granted by a shareholder

Key Honesty, a shareholder of the Company, has granted share awards to selected employees of the Group in 2022. Details of the share awards granted by the shareholder are set out in Note 23 to the condensed consolidated financial statements.

SUBSTANTIAL SHAREHOLDERS' INTERESTS

As at 30 June 2026, the following persons had interests or short positions in the shares or underlying shares of the Company which are required to be disclosed to the Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO or which are recorded in the register required to be kept by the Company under Section 336 of the SFO:

LONG POSITIONS

Name of Substantial Shareholder	Capacity/ Nature of Interest	Number of shares held	Number of underlying shares held	Total interests in shares/ underlying shares	Approximate % of the issued shares of the Company ⁽¹⁾
Cai Dong Chen	Beneficial owner	479,910,960	—	3,040,956,670	26.39%
	Interest of controlled corporation	2,561,045,710 ⁽²⁾	—		
True Ally Holdings Limited	Beneficial owner	948,249,600	—	2,561,045,710	22.23%
	Interest of controlled corporation	1,612,796,110	—		
Massive Giant Group Limited	Beneficial owner	1,218,834,470	—	1,218,834,470	10.58%
Common Success International Limited	Beneficial owner	728,796,313	—	728,796,313	6.33%

Notes:

(1) Based on 11,522,451,732 Shares in issue as at 30 June 2026.

(2) Mr. Cai Dong Chen is deemed to be interested in 2,561,045,710 shares, comprising (i) 367,081,640 shares directly held by Key Honesty, a direct wholly-owned subsidiary of True Ally, (ii) 1,218,834,470 shares directly held by Massive Giant Group Limited, a direct wholly-owned subsidiary of True Ally, (iii) 948,249,600 shares directly held by True Ally, which is directly wholly-owned by Mr. Cai Dong Chen and (iv) 26,880,000 shares directly held by Harmonic Choice Limited by virtue of his interests in a chain of corporations holding Harmonic Choice Limited, namely Massive Top Limited, of which March Rise Limited, Zhongyihe and True Ally own 75%, 15% and 10%, respectively. March Rise Limited in turn is owned as to 40% by True Ally and 60% by Zhongyihe, the general partner of which is Mr. Cai Dong Chen.

Other than as disclosed above, the Company has not been notified of any other interests or short positions in the shares and underlying shares of the Company as at 30 June 2026.

CHANGES IN INFORMATION OF DIRECTORS

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes in information of the director(s) of the Company, as notified to the Company, subsequent to the date of the 2025 Annual Report are set out below

Name of Director	Details of Changes
Mr. LAW Cheuk Kin Stephen	Appointed as an independent non-executive director of China Resources Gas Group Limited (listed on the Stock Exchange, Stock Code: 1193.HK) on 27 March 2026

CORPORATE GOVERNANCE

The Company has complied with all the code provisions in the Corporate Governance Code contained in Appendix C1 of the Rules Governing the Listing of Securities on the Stock Exchange throughout the six months ended 30 June 2026.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 of the Listing Rules. In response to specific enquiry mode, all directors confirmed that they have complied with the required standard set out in the Model Code throughout the six months ended 30 June 2026.

REVIEW OF INTERIM RESULTS

The interim results for the six months ended 30 June 2026 have been reviewed by the external auditor and audit committee of the Company.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's securities listed on the Stock Exchange (including sale of treasury shares, if any), except that the trustee of the Company's share award scheme adopted on 25 March 2026 (the "2026 Share Award Scheme") purchased a total of 46,178,000 shares of the Company on the Stock Exchange to be held on trust for a total consideration of approximately HK\$321,086,000 (equivalent to approximately RMB279,699,000), pursuant to the terms and conditions of the 2026 Share Award Scheme.

CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Thursday, 22 October 2026 to Monday, 26 October 2026, both days inclusive, during which period no transfer of shares will be effected. The record date for entitlement to the interim dividend is Monday, 26 October 2026. In order to qualify for the interim dividend, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Wednesday, 21 October 2026.